Healthcare Realty Trust (HR) 8-K 9 Aug 22 Other Events Financial data

Cover Page

Cover Page	Aug. 09, 2022
Entity Information [Line Items]
Document Type	8-K
Document Period End Date	Aug. 09, 2022
Entity Registrant Name	Healthcare Realty Trust Incorporated
Entity Incorporation, State or Country Code	MD
Entity File Number	001-35568
Entity Tax Identification Number	20-4738467
Entity Address, Address Line One	3310 West End Avenue, Suite 700
Entity Address, City or Town	Nashville,
Entity Address, State or Province	TN
Entity Address, Postal Zip Code	37203
City Area Code	(615)
Local Phone Number	269-8175
Title of 12(b) Security	Class A Common Stock, $0.01 par value per share
Trading Symbol	HR
Security Exchange Name	NYSE
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Entity Emerging Growth Company	false
Entity Central Index Key	0001360604
Amendment Flag	false
Healthcare Trust of America Holdings, LP (HTALP)
Entity Information [Line Items]
Entity Registrant Name	Healthcare Realty Holdings, L.P.
Entity Incorporation, State or Country Code	DE
Entity File Number	333-190916
Entity Tax Identification Number	20-4738347
Entity Emerging Growth Company	false
Entity Central Index Key	0001495491
Amendment Flag	false

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Real estate investments:
Land	$ 648,394	$ 640,382
Building and improvements	6,774,818	6,688,516
Lease intangibles	382,738	404,714
Construction in progress	15,252	32,685
Real estate investments, gross	7,821,202	7,766,297
Accumulated depreciation and amortization	(1,699,546)	(1,598,468)
Real estate investments, net	6,121,656	6,167,829
Assets held for sale, net	0	27,070
Investment in unconsolidated joint venture	62,070	62,834
Cash and cash equivalents	29,714	52,353
Restricted cash	4,559	4,716
Receivables and other assets, net	360,433	334,941
Right-of-use assets - operating leases, net	227,603	229,226
Other intangibles, net	9,315	10,720
Total assets	6,815,350	6,889,689
Liabilities:
Debt	3,094,643	3,028,122
Accounts payable and accrued liabilities	171,673	198,078
Liabilities of assets held for sale	0	262
Derivative financial instruments - interest rate swaps	0	5,069
Security deposits, prepaid rent and other liabilities	82,071	86,225
Lease liabilities - operating leases	196,991	196,286
Intangible liabilities, net	28,671	31,331
Total liabilities	3,574,049	3,545,373
Commitments and contingencies
Equity/Partners' Capital:
Preferred stock, $0.01 par value; 200,000,000 shares authorized; none issued and outstanding	0	0
Class A common stock, $0.01 par value; 1,000,000,000 shares authorized; 229,072,922 and 228,879,846 shares issued and outstanding as of June 30, 2022 and December 31, 2021, respectively	2,291	2,289
Additional paid-in capital	5,182,766	5,178,132
Accumulated other comprehensive income (loss)	5,786	(7,041)
Cumulative dividends in excess of earnings	(2,032,181)	(1,915,776)
Total stockholders’ equity	3,158,662	3,257,604
Non-controlling interests	82,639	86,712
Total equity	3,241,301	3,344,316
Partners’ Capital:
Total liabilities and equity/partners' capital	6,815,350	6,889,689
Healthcare Trust of America Holdings, LP (HTALP)
Real estate investments:
Land	648,394	640,382
Building and improvements	6,774,818	6,688,516
Lease intangibles	382,738	404,714
Construction in progress	15,252	32,685
Real estate investments, gross	7,821,202	7,766,297
Accumulated depreciation and amortization	(1,699,546)	(1,598,468)
Real estate investments, net	6,121,656	6,167,829
Assets held for sale, net	0	27,070
Investment in unconsolidated joint venture	62,070	62,834
Cash and cash equivalents	29,714	52,353
Restricted cash	4,559	4,716
Receivables and other assets, net	360,433	334,941
Right-of-use assets - operating leases, net	227,603	229,226
Other intangibles, net	9,315	10,720
Total assets	6,815,350	6,889,689
Liabilities:
Debt	3,094,643	3,028,122
Accounts payable and accrued liabilities	171,673	198,078
Liabilities of assets held for sale	0	262
Derivative financial instruments - interest rate swaps	0	5,069
Security deposits, prepaid rent and other liabilities	82,071	86,225
Lease liabilities - operating leases	196,991	196,286
Intangible liabilities, net	28,671	31,331
Total liabilities	3,574,049	3,545,373
Commitments and contingencies
Partners’ Capital:
Limited partners’ capital, 4,050,493 and 4,142,408 OP Units issued and outstanding as of June 30, 2022 and December 31, 2021, respectively	82,369	86,442
General partners’ capital, 229,072,922 and 228,879,846 OP Units issued and outstanding as of June 30, 2022 and December 31, 2021, respectively	3,158,932	3,257,874
Total partners’ capital	3,241,301	3,344,316
Total liabilities and equity/partners' capital	$ 6,815,350	$ 6,889,689

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Jun. 30, 2022	Dec. 31, 2021
Equity:
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	200,000,000	200,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	1,000,000,000	1,000,000,000
Common stock, shares issued (in shares)	229,072,922	228,879,846
Common stock, shares outstanding (in shares)	229,072,922	228,879,846
Healthcare Trust of America Holdings, LP (HTALP)
Partners’ Capital:
Limited partner's capital, units issued (in shares)	4,050,493	4,142,408
Limited partner's capital, units outstanding (in shares)	4,050,493	4,142,408
General partner's capital, units issued (in shares)	229,072,922	228,879,846
General partner's capital, units outstanding (in shares)	229,072,922	228,879,846

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Revenues:
Rental income	$ 198,284	$ 188,494	$ 398,527	$ 379,844
Interest and other operating income	1,849	121	3,608	264
Total revenues	200,133	188,615	402,135	380,108
Expenses:
Rental	63,373	57,409	129,257	116,988
General and administrative	14,243	10,929	26,691	21,489
Merger-related costs	5,107	0	11,125	0
Transaction	97	66	241	162
Depreciation and amortization	75,051	74,977	150,437	151,251
Interest expense	24,760	23,133	48,700	46,119
Impairment	0	16,825	0	16,825
Total expenses	182,631	183,339	366,451	352,834
Gain (loss) on sale of real estate, net	0	32,753	(4)	32,753
Loss on extinguishment of debt, net	(3,615)	0	(3,615)	0
Income from unconsolidated joint venture	401	406	801	798
Other income	134	304	222	307
Net income	14,422	38,739	33,088	61,132
Net income attributable to non-controlling interests	(254)	(728)	(605)	(1,091)
Net income attributable to common stockholders/unitholders	$ 14,168	$ 38,011	$ 32,483	$ 60,041
Earnings per common share - basic
Net income attributable to common stockholders/unitholders (in dollars per share)	$ 0.06	$ 0.17	$ 0.14	$ 0.27
Earnings per common share - diluted
Net income attributable to common stockholders/unitholders (in dollars per share)	$ 0.06	$ 0.17	$ 0.14	$ 0.27
Weighted average common shares outstanding:
Basic (in shares/units)	229,074	218,822	229,026	218,787
Diluted (in shares/units)	233,125	222,326	233,086	222,297
Healthcare Trust of America Holdings, LP (HTALP)
Revenues:
Rental income	$ 198,284	$ 188,494	$ 398,527	$ 379,844
Interest and other operating income	1,849	121	3,608	264
Total revenues	200,133	188,615	402,135	380,108
Expenses:
Rental	63,373	57,409	129,257	116,988
General and administrative	14,243	10,929	26,691	21,489
Merger-related costs	5,107	0	11,125	0
Transaction	97	66	241	162
Depreciation and amortization	75,051	74,977	150,437	151,251
Interest expense	24,760	23,133	48,700	46,119
Impairment	0	16,825	0	16,825
Total expenses	182,631	183,339	366,451	352,834
Gain (loss) on sale of real estate, net	0	32,753	(4)	32,753
Loss on extinguishment of debt, net	(3,615)	0	(3,615)	0
Income from unconsolidated joint venture	401	406	801	798
Other income	134	304	222	307
Net income	14,422	38,739	33,088	61,132
Net income attributable to non-controlling interests	0	0	0	0
Net income attributable to common stockholders/unitholders	$ 14,422	$ 38,739	$ 33,088	$ 61,132
Earnings per common share - basic
Net income attributable to common stockholders/unitholders (in dollars per share)	$ 0.06	$ 0.17	$ 0.14	$ 0.28
Earnings per common share - diluted
Net income attributable to common stockholders/unitholders (in dollars per share)	$ 0.06	$ 0.17	$ 0.14	$ 0.28
Weighted average common shares outstanding:
Basic (in shares/units)	233,125	222,326	233,086	222,297
Diluted (in shares/units)	233,125	222,326	233,086	222,297

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Net income	$ 14,422	$ 38,739	$ 33,088	$ 61,132
Other comprehensive income
Change in unrealized gains on cash flow hedges	4,085	1,523	12,902	4,315
Total other comprehensive income	4,085	1,523	12,902	4,315
Total comprehensive income	18,507	40,262	45,990	65,447
Comprehensive income attributable to non-controlling interests	(281)	(754)	(681)	(1,161)
Total comprehensive income (loss) attributable to common stockholders/unitholders	18,226	39,508	45,309	64,286
Healthcare Trust of America Holdings, LP (HTALP)
Net income	14,422	38,739	33,088	61,132
Other comprehensive income
Change in unrealized gains on cash flow hedges	4,085	1,523	12,902	4,315
Total other comprehensive income	4,085	1,523	12,902	4,315
Total comprehensive income	18,507	40,262	45,990	65,447
Comprehensive income attributable to non-controlling interests	0	0	0	0
Total comprehensive income (loss) attributable to common stockholders/unitholders	$ 18,507	$ 40,262	$ 45,990	$ 65,447

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF EQUITY - USD ($) $ in Thousands	Total	Total Stockholders’ Equity	Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Income (Loss)	Cumulative Dividends in Excess of Earnings	Non-controlling Interests
Beginning balance at Dec. 31, 2020	$ 3,234,919	$ 3,174,239	$ 2,186	$ 4,916,784	$ (16,979)	$ (1,727,752)	$ 60,680
Beginning balance (in shares) at Dec. 31, 2020			218,578,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based award transactions, net	3,337	3,337	$ 3	3,334
Share-based award transactions, net (in shares)			354,000
Repurchase and cancellation of common stock	(3,248)	(3,248)	$ (1)	(3,247)
Repurchase and cancellation of common stock (in shares)			(119,000)
Redemption of non-controlling interest and other	0	255		255			(255)
Redemption of noncontrolling interest and other (in shares)			11,000
Dividends declared	(71,206)	(70,023)				(70,023)
Dividends declared							(1,183)
Net income	22,393	22,030				22,030	363
Other comprehensive income (loss)	2,792	2,748			2,748		44
Ending balance at Mar. 31, 2021	3,188,987	3,129,338	$ 2,188	4,917,126	(14,231)	(1,775,745)	59,649
Ending balance (in shares) at Mar. 31, 2021			218,824,000
Beginning balance at Dec. 31, 2020	3,234,919	3,174,239	$ 2,186	4,916,784	(16,979)	(1,727,752)	60,680
Beginning balance (in shares) at Dec. 31, 2020			218,578,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Other comprehensive income (loss)	4,315
Ending balance at Jun. 30, 2021	3,159,888	3,101,054	$ 2,188	4,919,353	(12,734)	(1,807,753)	58,834
Ending balance (in shares) at Jun. 30, 2021			218,826,000
Beginning balance at Mar. 31, 2021	3,188,987	3,129,338	$ 2,188	4,917,126	(14,231)	(1,775,745)	59,649
Beginning balance (in shares) at Mar. 31, 2021			218,824,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based award transactions, net	2,065	2,065		2,065
Share-based award transactions, net (in shares)			6,000
Repurchase and cancellation of common stock	(129)	(129)		(129)
Repurchase and cancellation of common stock (in shares)			(5,000)
Redemption of non-controlling interest and other	0	291		291			(291)
Redemption of noncontrolling interest and other (in shares)			13,000
Dividends declared	(71,297)	(70,019)				(70,019)
Dividends declared							(1,278)
Net income	38,739	38,011				38,011	728
Other comprehensive income (loss)	1,523	1,497			1,497		26
Ending balance at Jun. 30, 2021	3,159,888	3,101,054	$ 2,188	4,919,353	(12,734)	(1,807,753)	58,834
Ending balance (in shares) at Jun. 30, 2021			218,826,000
Beginning balance at Dec. 31, 2021	$ 3,344,316	3,257,604	$ 2,289	5,178,132	(7,041)	(1,915,776)	86,712
Beginning balance (in shares) at Dec. 31, 2021	228,879,846		228,880,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based award transactions, net	$ 2,024	2,024	$ 1	2,023
Share-based award transactions, net (in shares)			154,000
Repurchase and cancellation of common stock	(1,640)	(1,640)		(1,640)
Repurchase and cancellation of common stock (in shares)			(50,000)
Redemption of non-controlling interest and other	0	2,065	$ 1	2,064			(2,065)
Redemption of noncontrolling interest and other (in shares)			92,000
Dividends declared	(75,816)	(74,443)				(74,443)
Dividends declared							(1,373)
Net income	18,666	18,315				18,315	351
Other comprehensive income (loss)	8,817	8,768			8,768		49
Ending balance at Mar. 31, 2022	3,296,367	3,212,693	$ 2,291	5,180,579	1,727	(1,971,904)	83,674
Ending balance (in shares) at Mar. 31, 2022			229,076,000
Beginning balance at Dec. 31, 2021	$ 3,344,316	3,257,604	$ 2,289	5,178,132	(7,041)	(1,915,776)	86,712
Beginning balance (in shares) at Dec. 31, 2021	228,879,846		228,880,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Other comprehensive income (loss)	$ 12,902
Ending balance at Jun. 30, 2022	$ 3,241,301	3,158,662	$ 2,291	5,182,766	5,786	(2,032,181)	82,639
Ending balance (in shares) at Jun. 30, 2022	229,072,922		229,073,000
Beginning balance at Mar. 31, 2022	$ 3,296,367	3,212,693	$ 2,291	5,180,579	1,727	(1,971,904)	83,674
Beginning balance (in shares) at Mar. 31, 2022			229,076,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based award transactions, net	2,191	2,191		2,191
Share-based award transactions, net (in shares)			3,000
Repurchase and cancellation of common stock	(4)	(4)		(4)
Dividends declared	(75,760)	(74,445)				(74,445)
Dividends declared							(1,315)
Net income	14,422	14,168				14,168	254
Other comprehensive income (loss)	4,085	4,059			4,059		26
Ending balance at Jun. 30, 2022	$ 3,241,301	$ 3,158,662	$ 2,291	$ 5,182,766	$ 5,786	$ (2,032,181)	$ 82,639
Ending balance (in shares) at Jun. 30, 2022	229,072,922		229,073,000

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENTS OF EQUITY (Parenthetical) - $ / shares	3 Months Ended
	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2021	Mar. 31, 2021
Statement of Stockholders' Equity [Abstract]
Dividends declared (in dollars per share)	$ 0.325	$ 0.325	$ 0.320	$ 0.320

CONDENSED CONSOLIDATED STATEM_5

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN PARTNERS' CAPITAL - USD ($) shares in Thousands, $ in Thousands	Total	Healthcare Trust of America Holdings, LP (HTALP)	Healthcare Trust of America Holdings, LP (HTALP) General Partners’ Capital	Healthcare Trust of America Holdings, LP (HTALP) Limited Partners’ Capital
Balance as of beginning of period at Dec. 31, 2020		$ 3,234,919	$ 3,174,509	$ 60,410
Balance as of beginning of period (in shares) at Dec. 31, 2020			218,578	3,520
Increase (Decrease) in Partners' Capital [Roll Forward]
Share-based award transactions, net		3,337	$ 3,337
Share-based award transactions, net (in shares)			354
Redemption and cancellation of general partner units (in shares)			(119)
Redemption and cancellation of general partner OP Units		(3,248)	$ (3,248)
Redemption of limited partner OP Units and other (in shares)			11	(11)
Redemption of limited partner OP Units and other		0	$ 255	$ (255)
Distributions declared		(71,206)	(70,023)	(1,183)
Net income		22,393	22,030	363
Other comprehensive income (loss)	$ 2,792	2,792	2,748	44
Balance as of end of period at Mar. 31, 2021		3,188,987	$ 3,129,608	$ 59,379
Balance as of end of period (in shares) at Mar. 31, 2021			218,824	3,509
Balance as of beginning of period at Dec. 31, 2020		3,234,919	$ 3,174,509	$ 60,410
Balance as of beginning of period (in shares) at Dec. 31, 2020			218,578	3,520
Increase (Decrease) in Partners' Capital [Roll Forward]
Net income	60,041	61,132
Other comprehensive income (loss)	4,315	4,315
Balance as of end of period at Jun. 30, 2021		3,159,888	$ 3,101,324	$ 58,564
Balance as of end of period (in shares) at Jun. 30, 2021			218,826	3,496
Balance as of beginning of period at Mar. 31, 2021		3,188,987	$ 3,129,608	$ 59,379
Balance as of beginning of period (in shares) at Mar. 31, 2021			218,824	3,509
Increase (Decrease) in Partners' Capital [Roll Forward]
Issuance of general partner OP Units (in shares)				0
Issuance of general partner OP Units		0		$ 0
Share-based award transactions, net		2,065	$ 2,065
Share-based award transactions, net (in shares)			(6)
Redemption and cancellation of general partner units (in shares)			(5)
Redemption and cancellation of general partner OP Units		(129)	$ (129)
Redemption of limited partner OP Units and other (in shares)			13	(13)
Redemption of limited partner OP Units and other		0	$ 291	$ (291)
Distributions declared		(71,297)	(70,019)	(1,278)
Net income	38,011	38,739	38,011	728
Other comprehensive income (loss)	1,523	1,523	1,497	26
Balance as of end of period at Jun. 30, 2021		3,159,888	$ 3,101,324	$ 58,564
Balance as of end of period (in shares) at Jun. 30, 2021			218,826	3,496
Balance as of beginning of period at Dec. 31, 2021		3,344,316	$ 3,257,874	$ 86,442
Balance as of beginning of period (in shares) at Dec. 31, 2021			228,880	4,142
Increase (Decrease) in Partners' Capital [Roll Forward]
Share-based award transactions, net		2,024	$ 2,024
Share-based award transactions, net (in shares)			154
Redemption and cancellation of general partner units (in shares)			(50)
Redemption and cancellation of general partner OP Units		(1,640)	$ (1,640)
Redemption of limited partner OP Units and other (in shares)			92	(92)
Redemption of limited partner OP Units and other		0	$ 2,065	$ (2,065)
Distributions declared		(75,816)	(74,443)	(1,373)
Net income		18,666	18,315	351
Other comprehensive income (loss)	8,817	8,817	8,768	49
Balance as of end of period at Mar. 31, 2022		3,296,367	$ 3,212,963	$ 83,404
Balance as of end of period (in shares) at Mar. 31, 2022			229,076	4,050
Balance as of beginning of period at Dec. 31, 2021		3,344,316	$ 3,257,874	$ 86,442
Balance as of beginning of period (in shares) at Dec. 31, 2021			228,880	4,142
Increase (Decrease) in Partners' Capital [Roll Forward]
Net income	32,483	33,088
Other comprehensive income (loss)	12,902	12,902
Balance as of end of period at Jun. 30, 2022		3,241,301	$ 3,158,932	$ 82,369
Balance as of end of period (in shares) at Jun. 30, 2022			229,073	4,050
Balance as of beginning of period at Mar. 31, 2022		3,296,367	$ 3,212,963	$ 83,404
Balance as of beginning of period (in shares) at Mar. 31, 2022			229,076	4,050
Increase (Decrease) in Partners' Capital [Roll Forward]
Share-based award transactions, net		2,191	$ 2,191
Share-based award transactions, net (in shares)			(3)
Redemption and cancellation of general partner OP Units		(4)	$ (4)
Distributions declared		(75,760)	(74,445)	$ (1,315)
Net income	14,168	14,422	14,168	254
Other comprehensive income (loss)	$ 4,085	4,085	4,059	26
Balance as of end of period at Jun. 30, 2022		$ 3,241,301	$ 3,158,932	$ 82,369
Balance as of end of period (in shares) at Jun. 30, 2022			229,073	4,050

CONDENSED CONSOLIDATED STATEM_6

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN PARTNERS' CAPITAL (Parenthetical) - $ / shares	3 Months Ended
	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2021	Mar. 31, 2021
Dividends declared (in dollars per share)	$ 0.325	$ 0.325	$ 0.320	$ 0.320
Healthcare Trust of America Holdings, LP (HTALP)
Dividends declared (in dollars per share)	$ 0.325	$ 0.325	$ 0.320	$ 0.320

CONDENSED CONSOLIDATED STATEM_7

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Cash flows from operating activities:
Net income	$ 33,088	$ 61,132
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	142,174	142,062
Share-based compensation expense	4,216	5,402
Income from unconsolidated joint venture	(801)	(798)
Distributions from unconsolidated joint venture	1,565	1,565
Impairment	0	16,825
Loss (gain) on sale of real estate, net	4	(32,753)
Loss on extinguishment of debt, net	3,615	0
Changes in operating assets and liabilities:
Receivables and other assets, net	(8,445)	10,540
Accounts payable and accrued liabilities	(22,188)	(8,552)
Security deposits, prepaid rent and other liabilities	(775)	(4,496)
Net cash provided by operating activities	152,453	190,927
Cash flows from investing activities:
Investments in real estate	(25,855)	(50,628)
Development of real estate	(22,478)	(33,983)
Proceeds from the sale of real estate	26,791	65,349
Capital expenditures	(54,954)	(53,471)
Collection of real estate notes receivable	0	15,405
Loan origination fees	325	0
Advances on real estate notes receivable	(3,734)	(61,020)
Net cash used in investing activities	(79,905)	(118,348)
Cash flows from financing activities:
Borrowings on unsecured revolving credit facility	150,000	100,000
Payments on unsecured revolving credit facility	(85,000)	(55,000)
Deferred financing costs	(7,154)	0
Repurchase and cancellation of common stock	(1,646)	(3,377)
Dividends paid	(148,826)	(140,022)
Distributions paid to non-controlling interest of limited partners	(2,718)	(2,607)
Net cash used in financing activities	(95,344)	(101,006)
Net change in cash, cash equivalents and restricted cash	(22,796)	(28,427)
Cash, cash equivalents and restricted cash - beginning of period	57,069	118,765
Cash, cash equivalents and restricted cash - end of period	34,273	90,338
Healthcare Trust of America Holdings, LP (HTALP)
Cash flows from operating activities:
Net income	33,088	61,132
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	142,174	142,062
Share-based compensation expense	4,216	5,402
Income from unconsolidated joint venture	(801)	(798)
Distributions from unconsolidated joint venture	1,565	1,565
Impairment	0	16,825
Loss (gain) on sale of real estate, net	4	(32,753)
Loss on extinguishment of debt, net	3,615	0
Changes in operating assets and liabilities:
Receivables and other assets, net	(8,445)	10,540
Accounts payable and accrued liabilities	(22,188)	(8,552)
Security deposits, prepaid rent and other liabilities	(775)	(4,496)
Net cash provided by operating activities	152,453	190,927
Cash flows from investing activities:
Investments in real estate	(25,855)	(50,628)
Development of real estate	(22,478)	(33,983)
Proceeds from the sale of real estate	26,791	65,349
Capital expenditures	(54,954)	(53,471)
Collection of real estate notes receivable	0	15,405
Loan origination fees	325	0
Advances on real estate notes receivable	(3,734)	(61,020)
Net cash used in investing activities	(79,905)	(118,348)
Cash flows from financing activities:
Borrowings on unsecured revolving credit facility	150,000	100,000
Payments on unsecured revolving credit facility	(85,000)	(55,000)
Deferred financing costs	(7,154)	0
Repurchase and cancellation of general partner units	(1,646)	(3,377)
Distributions paid to general partner	(148,826)	(140,022)
Distributions paid to limited partners and redeemable non-controlling interests	(2,718)	(2,607)
Net cash used in financing activities	(95,344)	(101,006)
Net change in cash, cash equivalents and restricted cash	(22,796)	(28,427)
Cash, cash equivalents and restricted cash - beginning of period	57,069	118,765
Cash, cash equivalents and restricted cash - end of period	$ 34,273	$ 90,338

Organization and Description of

Organization and Description of Business	6 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Description of Business	Organization and Description of Business HTA, a Maryland corporation, and HTALP, a Delaware limited partnership, were incorporated or formed, as applicable, on April 20, 2006. HTA operates as a REIT and is the general partner of HTALP, which is the operating partnership, in an umbrella partnership, or “UPREIT” structure. HTA has qualified and intends to continue to be taxed as a REIT for federal income tax purposes under the applicable sections of the Internal Revenue Code of 1986, as amended. We own real estate primarily consisting of medical office buildings (“MOBs”) located on or adjacent to hospital campuses or in off-campus, community core outpatient locations across 32 states within the United States, and we lease space to tenants primarily consisting of health systems, research and academic institutions, and various sized physician practices. Through our full-service operating platform, we provide leasing, asset management, acquisitions, development and other related services for our properties. Our primary objective is to maximize stockholder value with growth through strategic investments that provide an attractive risk-adjusted return for our stockholders by consistently increasing our cash flow. In pursuing this objective, we: (i) seek internal growth through proactive asset management, leasing, building services and property management oversight; (ii) target accretive acquisitions and developments of MOBs in markets with attractive demographics that complement our existing portfolio; and (iii) actively manage our balance sheet to maintain flexibility with conservative leverage. Additionally, from time to time we consider, on an opportunistic basis, significant portfolio acquisitions that we believe fit our core business and we expect to enhance our existing portfolio. Merger with Healthcare Realty Trust Incorporated On July 20, 2022, Healthcare Trust of America, Inc. (the “Company”), a Maryland corporation, Healthcare Trust of America Holdings, LP, a Delaware limited partnership (the “Company OP”) of which the Company is the sole general partner, HR Acquisition 2, LLC, a Maryland limited liability company and a direct, wholly owned subsidiary of the Company (“Merger Sub”), consummated a Merger with Healthcare Realty Trust Incorporated, a Maryland corporation (“HR”), pursuant to a definitive Agreement and Plan of Merger (the “Merger Agreement”) dated February 28, 2022, which was unanimously approved by the boards of directors of the Company and HR. Upon the terms and subject to the conditions set forth in the Merger Agreement, Merger Sub merged with and into HR, with HR surviving the Merger (the “Merger”). Pursuant to the terms in the Merger Agreement, each outstanding share of Common Stock, $0.01 par value per share, of HR (“HR Common Stock”) was converted into the right to receive 1.0 (the “Exchange Ratio”) share of Class A Common Stock, $0.01 par value per share, of the Company (“Company Common Stock” and, such consideration, the “Merger Consideration”). Pursuant to the closing of the Merger and the other transactions contemplated therein, the holders of shares of Company Common Stock issued and outstanding on July 19, 2022 received a special distribution in the amount of $4.82 in cash per share of Company Common Stock held on such date (the “Special Distribution Payment”). Except where noted, the condensed consolidated financial statements for the quarter ended June 30, 2022, descriptions of the Company, legal structure, employees, management, board of directors, customers, capitalization, risks and uncertainties, plans and objectives, strategy, and portfolio information solely relate to the Company prior to the consummation of the Merger without giving specific consideration to the combined entity post-Merger or plans of the Company’s management after the Merger. COVID-19 Pandemic

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies The summary of significant accounting policies presented below is designed to assist in understanding our condensed consolidated financial statements. Such condensed consolidated financial statements and the accompanying notes are the representations of our management, who are responsible for their integrity and objectivity. These accounting policies conform to generally accepted accounting principles in the U.S. (“GAAP”) in all material respects and have been consistently applied in preparing our accompanying condensed consolidated financial statements. Basis of Presentation Our accompanying condensed consolidated financial statements include our accounts and those of our subsidiaries and any consolidated variable interest entities (“VIEs”). All inter-company balances and transactions have been eliminated in the accompanying condensed consolidated financial statements. Interim Unaudited Financial Data Our accompanying condensed consolidated financial statements have been prepared by us in accordance with GAAP in conjunction with the rules and regulations of the SEC. Certain information and footnote disclosures required for annual financial statements have been condensed or excluded pursuant to SEC rules and regulations. Accordingly, our accompanying condensed consolidated financial statements (i) do not include all information and footnotes required by GAAP for complete financial statements, and (ii) reflect all adjustments, which are, in our opinion, of a normal recurring nature and necessary for a fair presentation of our financial position, results of operations and cash flows for the interim periods. Interim results of operations are not necessarily indicative of the results to be expected for the full year; such results may be less favorable for the full year. Our accompanying condensed consolidated financial statements should be read in conjunction with our audited consolidated financial statements and the notes thereto included in our 2021 Annual Report on Form 10-K. Principles of Consolidation The condensed consolidated financial statements include the accounts of our subsidiaries and consolidated joint venture arrangements. The portions of the HTALP operating partnership not owned by us are presented as non-controlling interests on the accompanying condensed consolidated balance sheets and statements of operations, condensed consolidated statements of comprehensive income, and condensed consolidated statements of equity and changes in partners’ capital. Holders of OP Units are considered to be non-controlling interest holders in HTALP and their ownership interests are reflected as equity on the accompanying condensed consolidated balance sheets. Further, a portion of the earnings and losses of HTALP are allocated to non-controlling interest holders based on their respective ownership percentages. Upon conversion of OP Units to common stock, any difference between the fair value of the common stock issued and the carrying value of the OP Units converted to common stock is recorded as a component of equity. As of both June 30, 2022 and December 31, 2021, there were approximately 4.1 million of OP Units issued and outstanding held by non-controlling interest holders. VIEs are entities where investors lack sufficient equity at risk for the entity to finance its activities without additional subordinated financial support or where equity investors, as a group, lack one of the following: (i) the power to direct the activities that most significantly impact the entity’s economic performance; (ii) the obligation to absorb the expected losses of the entity; and (iii) the right to receive the expected returns of the entity. We consolidate our investment in VIEs when we determine that we are the primary beneficiary. A primary beneficiary is one that has both: (i) the power to direct the activities of the VIE that most significantly impacts the entity’s economic performance; and (ii) the obligation to absorb losses or the right to receive benefits of the VIE that could be significant to the entity. The HTALP operating partnership and our other joint venture arrangements are VIEs because the limited partners in those partnerships, although entitled to vote on certain matters, do not possess kick-out rights or substantive participating rights. Additionally, we determined that we are the primary beneficiary of our VIEs. Accordingly, we consolidate our interests in the HTALP operating partnership and in our other joint venture arrangements. However, because we hold what is deemed a majority voting interest in the HTALP operating partnership and our other joint venture arrangements, it qualifies for the exemption from providing certain disclosure requirements associated with investments in VIEs. Use of Estimates The preparation of our condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that effect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent asset and liabilities. These estimates are made and evaluated on an ongoing basis using information that is currently available as well as various other assumptions believed to be reasonable under the circumstances. Actual results could differ from those estimates, perhaps in adverse ways, and those estimates could be different under different assumptions or conditions. Cash, Cash Equivalents and Restricted Cash Cash and cash equivalents consist of all highly liquid investments with a maturity of three months or less when purchased. Restricted cash is typically comprised of: (i) reserve accounts for property taxes, insurance, capital and tenant improvements; (ii) collateral accounts for debt and interest rate swaps; (iii) 1031 exchange funds; and (iv) deposits for future investments. The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the accompanying condensed consolidated balance sheets to the combined amounts shown on the accompanying condensed consolidated statements of cash flows (in thousands): June 30, 2022 2021 Cash and cash equivalents $ 29,714 $ 19,796 Restricted cash 4,559 70,542 Total cash, cash equivalents and restricted cash $ 34,273 $ 90,338 Revenue Recognition Minimum annual rental revenue is recognized on a straight-line basis over the term of the related lease (including rent holidays). Differences between rental income recognized and amounts contractually due under the lease agreements are recorded as straight-line rent receivables. Tenant reimbursements, which is comprised of additional amounts recoverable from tenants for real estate taxes, common area maintenance and other certain operating expenses are recognized as revenue on a gross basis in the period in which the related recoverable expenses are incurred. We accrue revenue corresponding to these expenses on a quarterly basis to adjust recorded amounts to our best estimate of the final annual amounts to be billed. Subsequent to year-end, on a calendar year basis, we perform reconciliations on a lease-by-lease basis and bill or credit each tenant for any differences between the estimated expenses we billed and the actual expenses that were incurred. We recognize lease termination fees when there is a signed termination letter agreement, all of the conditions of the agreement have been met, and the tenant is no longer occupying the property. Rental income is reported net of amortization of inducements. The revenue recognition process is based on a five-step model to account for revenue arising from contracts with customers as outlined in ASC Topic 606 - Revenue from Contracts with Customers. We recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. We have identified all of our revenue streams and we have concluded that rental income from leasing arrangements represents a substantial portion of our revenue and is governed and evaluated with the adoption of ASC Topic 842 - Lessors - Certain Leases with Variable Lease Payments (“Topic 842”). Investments in Real Estate Depreciation expense of buildings and improvements for the three months ended June 30, 2022 and 2021 was $62.3 million and $60.7 million, respectively. Depreciation expense of buildings and improvements for the six months ended June 30, 2022 and 2021 was $124.6 million and $121.9 million, respectively. Leases As a lessor, we lease space in our MOBs primarily to medical enterprises for terms generally ranging from three Leases, for which we are the lessee, are classified as separate components on our accompanying condensed consolidated balance sheets. Operating leases are included as right-of-use (“ROU”) assets - operating leases, net, with a corresponding lease liability. Financing lease assets are included in receivables and other assets, net, with a corresponding lease liability in security deposits, prepaid rent and other liabilities. A lease liability is recognized for our obligation related to the lease and an ROU asset represents our right to use the underlying asset over the lease term. Refer to Note 7 - Leases in the accompanying notes to the condensed consolidated financial statements for more detail relating to our leases. Real Estate Held for Sale We consider properties held for sale once management commits to a plan to sell the property and has determined that the sale is probable and expected to occur within one year. Upon classification as held for sale, we record the property at the lower of its carrying amount or fair value, less costs to sell, and cease depreciation and amortization. The fair value is generally based on a discounted cash flow analysis, which involves management's best estimate of market participants' holding periods, market comparables, future occupancy levels, rental rates, capitalization rates, lease-up periods and capital requirements. As of June 30, 2022, the Company had no properties classified as held for sale. As of December 31, 2021, the Company had one property classified as held for sale. Real Estate Notes Receivable Real estate notes receivable consists of mezzanine and other real estate loans, which are generally collateralized by a pledge of the borrower’s ownership interest in the respective real estate owner and/or corporate guarantees . Real estate notes receivable are intended to be held-to-maturity and are recorded at amortized cost, net of unamortized loan origination costs and fees and allowance for credit losses. As of June 30, 2022, real estate notes receivable, net totaled $75.9 million. During the six months ended June 30, 2022, we recognized interest income of $3.2 million related to real estate notes receivable. The following table summarizes real estate notes receivable as of June 30, 2022 (in thousands): Stated Interest Rate Maximum Loan Commitment Outstanding Loan Amount Origination Date Maturity Date June 30, 2022 Mezzanine Loans - Texas (1) 6/24/2021 6/24/2024 8 % $ 54,119 $ 53,756 Mezzanine Loan - North Carolina 12/22/2021 12/22/2024 8 % 6,000 6,000 Mortgage Loan - Texas 6/30/2021 7/1/2022 10 % 15,000 15,000 Construction Loan - Florida 5/17/2022 2/27/2026 6 % 65,000 1,464 76,220 Accrued interest receivable 311 Unamortized fees and costs (659) Unearned revenue — $ 75,872 (1) Interest on these mezzanine loans is accrued and funded utilizing interest reserves, which is included in the maximum loan commitment, and such accrued interest is added to the note receivable balance. Pursuant to ASC Topic 326 - Financial Instruments - Credit Losses ( “Topic 326”) , we adopted a policy to evaluate current expected credit losses at the inception of loans qualifying for treatment under Topic 326. We utilize a probability of default method approach for estimating current expected credit losses and have determined that the current risk of credit loss is remote. Accordingly, we have recorded no reserve for credit loss as of June 30, 2022. Unconsolidated Joint Ventures We account for our investments in unconsolidated joint ventures using the equity method of accounting because we have the ability to exercise significant influence, but not control, over the financial and operational policy decisions of the investments. Using the equity method of accounting, the initial investment is recognized at cost and subsequently adjusted for our share of the net income and any distributions from the joint venture. As of June 30, 2022 and December 31, 2021, we had a 50% interest in one such investment with a carrying value and maximum exposure to risk of $62.1 million and $62.8 million, respectively, which is recorded in investment in unconsolidated joint venture on the accompanying condensed consolidated balance sheets. We record our share of net income in income from unconsolidated joint venture on the accompanying condensed consolidated statements of operations. For each of the three months ended June 30, 2022 and 2021, we recognized income of $0.4 million. For each of the six months ended June 30, 2022 and 2021, we recognized income of $0.8 million. Recently Issued or Adopted Accounting Pronouncements Recently Adopted Accounting Pronouncements ASU 2021-05, Leases (Topic 842): Lessors - Certain Leases with Variable Lease Payments In July 2021, the FASB issued ASU 2021-05, which amends the lease classification requirements for lessors when classifying and accounting for a lease with variable lease payments that do not depend on a reference index or a rate. The update provides criteria, that if met, the lease would be classified and accounted for as an operating lease. The update is effective for reporting periods beginning after December 15, 2021, with early adoption permitted. We adopted ASU 2021-05 effective as of January 1, 2022. The adoption of this standard did not have a material impact on our financial statements. Recently Issued Accounting Pronouncements ASU 2021-01, Reference Rate Reform (Topic 848) In January 2021, the FASB issued ASU 2021-01, which amends the scope of ASU 2020-04. The amendments of ASU 2021-01 clarify that certain optional expedients and exceptions to Topic 848 for contract modification and hedge accounting apply to derivatives that are affected by the discounting transition. For information related to the Company's current cash flow hedges, refer to Note 9 - Derivative Financial Instruments and Hedging Activities. The amendments are elective and effective immediately for contract modifications made through December 31, 2022. We do not expect that this ASU will have a material impact on our financial statements. Subsequent Events The Company has evaluated events subsequent to June 30, 2022 to assess the need for potential recognition or disclosure in this report. Such events were evaluated through the date these financial statements were available to be issued, which was August 9, 2022 as it relates to events through July 20, 2022, or the date of the consummation of the Merger. Based upon this evaluation, it was determined that no subsequent events occurred that require recognition or disclosure in the financial statements that have either not been disclosed elsewhere in this report or reported in the Form 10-Q of Healthcare Realty Trust Incorporated as of and for the three and six months ended June 30, 2022, including any filings incorporated by reference into such report.

Investments in Real Estate

Investments in Real Estate	6 Months Ended
	Jun. 30, 2022
Investments [Abstract]
Investments in Real Estate	Investments in Real Estate For the six months ended June 30, 2022, our investments had an aggregate purchase price of $25.7 million. As part of these investments, we incurred approximately $0.2 million of capitalized costs. The allocations for these investments, in which we own a controlling financial interest, are set forth below in the aggregate for the six months ended June 30, 2022 and 2021, respectively (in thousands): Six Months Ended June 30, 2022 2021 Land $ 3,812 $ 1,093 Building and improvements 19,761 45,629 In place leases 2,121 5,291 Below market leases (28) (79) Above market leases — 66 ROU assets — (1,372) Net real estate assets acquired 25,666 50,628 Other, net — 2,397 Aggregate purchase price $ 25,666 $ 53,025 The acquired intangible assets and liabilities referenced above had weighted average lives of the following terms for the six months ended June 30, 2022 and 2021, respectively (in years): Six Months Ended June 30, 2022 2021 Acquired intangible assets 4.2 4.2 Acquired intangible liabilities 4.1 5.7

Dispositions and Impairment

Dispositions and Impairment	6 Months Ended
	Jun. 30, 2022
Discontinued Operations and Disposal Groups [Abstract]
Dispositions and Impairment	Dispositions and Impairment Dispositions During the six months ended June 30, 2022, we closed the sale of a tenant purchase option on one of our MOBs located in Georgia for a gross sales price of $26.8 million, resulting in a net loss to us of approximately four thousand dollars. During the six months ended June 30, 2021, we sold a 13 property portfolio with locations in Tennessee and Virginia for a gross sales price of $67.5 million, resulting in a net gain to us of approximately $32.8 million. Impairment During the six months ended June 30, 2022, we recorded no impairment charges. During the six months ended June 30, 2021, we recorded impairment charges of $16.8 million on two properties, for which the holding period was revised by the Company to be less than the previously estimated useful life. The estimated fair values were based on a purchase option and a pending sales agreement, both of which were executed subsequent to June 30, 2021.

Intangible Assets and Liabiliti

Intangible Assets and Liabilities	6 Months Ended
	Jun. 30, 2022
Identified Intangibles, Net [Abstract]
Intangible Assets and Liabilities	Intangible Assets and Liabilities Intangible assets and liabilities consisted of the following as of June 30, 2022 and December 31, 2021, respectively (in thousands, except with respect to the weighted average remaining amortization terms): June 30, 2022 December 31, 2021 Balance Weighted Average Remaining Balance Weighted Average Remaining Assets: In place leases $ 334,807 9.3 $ 349,863 9.3 Tenant relationships 47,931 10.9 54,851 10.8 Above market leases 20,548 6.8 21,537 6.9 403,286 426,251 Accumulated amortization (210,279) (213,801) Total $ 193,007 9.3 $ 212,450 9.3 Liabilities: Below market leases $ 53,695 14.6 $ 55,073 14.3 Accumulated amortization (25,024) (23,742) Total $ 28,671 14.6 $ 31,331 14.3 The following is a summary of the net intangible amortization for the three and six months ended June 30, 2022 and 2021, respectively (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Amortization recorded against rental income related to above and (below) market leases $ (634) $ (641) $ (1,283) $ (1,233) Amortization expense related to in place leases and tenant relationships 9,843 11,340 20,159 23,227

Receivables and Other Assets

Receivables and Other Assets	6 Months Ended
	Jun. 30, 2022
Receivables and Other Assets [Abstract]
Receivables and Other Assets	Receivables and Other Assets Receivables and other assets consisted of the following as of June 30, 2022 and December 31, 2021, respectively (in thousands): June 30, 2022 December 31, 2021 Tenant receivables, net $ 10,131 $ 10,477 Other receivables, net 10,335 6,098 Deferred financing costs, net 7,697 7,055 Deferred leasing costs, net 48,418 45,008 Straight-line rent receivables, net 149,602 142,604 Prepaid expenses, deposits, equipment and other, net 34,549 38,301 Derivative financial instruments - interest rate swaps 7,721 — Real estate notes receivable, net 75,872 69,114 Finance ROU asset, net 16,108 16,284 Total $ 360,433 $ 334,941 The following is a summary of the amortization of deferred leasing costs and financing costs for the three and six months ended June 30, 2022 and 2021, respectively (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Amortization expense related to deferred leasing costs $ 2,296 $ 2,204 $ 4,523 $ 4,427 Interest expense related to deferred financing costs 1,560 431 2,913 862

Leases

Leases	6 Months Ended
	Jun. 30, 2022
Leases [Abstract]
Leases	Leases For the three and six months ended June 30, 2022, we added one new ground lease that commenced in June 2022. Based on our analysis, we concluded that its classification was an operating lease. Lessee - Maturity of Lease Liabilities The following table summarizes the future minimum lease obligations of our operating and finance leases as of June 30, 2022 (in thousands): Year Operating Leases Finance Leases 2022 $ 5,378 $ 316 2023 10,884 635 2024 10,411 640 2025 9,899 645 2026 9,901 656 2027 9,886 668 Thereafter 591,325 36,856 Total undiscounted lease payments $ 647,684 $ 40,416 Less: Interest (450,693) (23,506) Present value of lease liabilities $ 196,991 $ 16,910 Lessor - Lease Revenues and Maturity of Future Minimum Rents For the three months ended June 30, 2022 and 2021, we recognized $198.0 million and $187.4 million, respectively, of rental and other lease-related income related to our operating leases, of which $47.4 million and $42.2 million, respectively, were variable lease payments. For the six months ended June 30, 2022 and 2021, we recognized $397.3 million and $377.8 million, respectively, of rental and other lease-related income related to our operating leases, of which $95.5 million and $87.3 million, respectively, were variable lease payments. The following table summarizes the future minimum rent contractually due under operating leases, excluding tenant reimbursements of certain costs, as of June 30, 2022 (in thousands): Year Amount 2022 $ 290,284 2023 551,493 2024 495,354 2025 436,400 2026 388,471 2027 318,837 Thereafter 1,345,024 Total $ 3,825,863

Debt

Debt	6 Months Ended
	Jun. 30, 2022
Debt Disclosure [Abstract]
Debt	Debt Debt consisted of the following as of June 30, 2022 and December 31, 2021, respectively (in thousands): June 30, 2022 December 31, 2021 Unsecured revolving credit facility $ 65,000 $ — Unsecured term loans 500,000 500,000 Unsecured senior notes 2,550,000 2,550,000 Fixed rate mortgages — — $ 3,115,000 $ 3,050,000 Deferred financing costs, net (16,426) (17,975) Discount, net (3,931) (3,903) Total $ 3,094,643 $ 3,028,122 Unsecured Credit Agreement Unsecured Revolving Credit Facility due 2025 On October 6, 2021, we entered into a third amended and restated revolving credit and term loan agreement (the “Credit Agreement”), which includes an unsecured revolving credit facility in an aggregate maximum principal amount of $1.0 billion (the “Revolver”) and a term loan facility in an aggregate maximum principal amount of $300.0 million (the “Term Loan”). The Credit Agreement extended the maturities of the unsecured revolving credit facility and the unsecured term loan to October 31, 2025. The maximum principal amount of the Unsecured Credit Agreement may be increased by up to $750.0 million, subject to certain conditions, for a total principal amount of $2.05 billion. Borrowings under the Revolver bear interest at a per annum rate equal to LIBOR plus a margin ranging from 0.725% to 1.40% based on our credit rating. We are also required to pay a facility fee on the aggregate commitments under the Revolver at a per annum rate ranging from 0.125% to 0.30% based on our credit rating. We incurred financing costs of $6.2 million in relation to the credit facility, which are being amortized through the maturity date. As of June 30, 2022, we had $65.0 million outstanding under this unsecured revolving credit facility. The margin associated with our borrowings was 0.85% per annum and the facility fee was 0.20% per annum. All amounts outstanding under the Revolver were fully repaid on July 20, 2022 as part of the Merger. Unsecured Term Loan due 2025 Under the Unsecured Credit Agreement as noted above, we have a $300.0 million unsecured term loan, guaranteed by HTA, with a maturity date of October 31, 2025. Borrowings under this unsecured term loan bear interest at a per annum rate equal to LIBOR, plus a margin ranging from 0.80% to 1.60% per annum based on our credit rating. The margin associated with our borrowings as of June 30, 2022 was 0.95% per annum. We incurred financing costs of $1.8 million in relation to the unsecured term loan, which are being amortized through the maturity date. We have interest rate swaps hedging the floating interest rate, which resulted in a fixed rate of 2.37% per annum, based on our current credit rating. The current hedging arrangement matures on February 1, 2023. As of June 30, 2022, we had $300.0 million under this unsecured term loan outstanding. This loan was fully repaid on July 20, 2022 as part of the Merger. Unsecured Term Loan Agreement due 2023 On May 13, 2022, we entered into a new $1.125 billion term loan agreement (the “Term Loan Agreement”) which includes an unsecured term loan facility in an aggregate principal amount not to exceed $1.125 billion (the “Term Loan Facility”). The Term Loan Facility is scheduled to mature on May 13, 2023. We have the right to extend the maturity date to May 13, 2024, pursuant to the Term Loan Agreement. Borrowings under the Term Loan Facility will bear interest at either the “Base Rate” or the “Adjusted Term SOFR Rate” upon our request as follows; (i) The Base Rate is equal to the greatest of the prime rate plus 1/2 of 1%, and a rate based on the Federal Reserve Bank of New York’s secured overnight term loan financing rate plus 1%, plus in any case a margin ranging from 0.00% to 0.600% per annum based on our credit rating or (ii) The “Adjusted Term SOFR Rate” is equal to a rate based on the Federal Reserve Bank of New York’s secured overnight term loan financing rate plus 0.10%, plus a margin ranging from 0.800% to 1.600% per annum based on our credit rating. We incurred financing costs of $1.8 million in relation to the Term Loan Facility, which are being amortized through the maturity date. On July 14, 2022, HTALP and HTA drew the full amount of the Term Loan Facility to fund the Special Distribution Payment pursuant to the terms of the Merger Agreement with HR. $200.0 Million Unsecured Term Loan due 2024 In 2018, HTALP entered into a modification of our $200.0 million unsecured term loan previously due in 2023. The modification decreased pricing at our current credit rating by 65 basis points and extended the maturity date to January 15, 2024. The other material terms of the unsecured term loan prior to the modification remained substantially unchanged. Borrowings under the unsecured term loan accrue interest at a rate equal to LIBOR, plus a margin ranging from 0.75% to 1.65% per annum based on our credit rating. The margin associated with our borrowings as of June 30, 2022 was 1.00% per annum. HTALP had interest rate swaps on the balance, which resulted in a fixed interest rate at 2.32% per annum. As of June 30, 2022, we had $200.0 million under this unsecured term loan outstanding. This loan was fully repaid on July 20, 2022 as part of the Merger. $600.0 Million Unsecured Senior Notes due 2026 In September 2019, in connection with the $650.0 million unsecured senior notes due 2030 referenced below, HTALP issued $250.0 million as additional unsecured senior notes to the $350.0 million aggregate principal of senior notes issued on July 12, 2016, all of which are guaranteed by HTA. These unsecured senior notes are registered under the Securities Act, and bear interest at 3.50% per annum which is payable semi-annually. Additionally, these unsecured senior notes were offered at 103.66% and 99.72%, respectively, of the principal amount thereof, with an effective yield to maturity of 2.89% and 3.53% per annum, respectively. As of June 30, 2022, we had $600.0 million of these unsecured senior notes outstanding that mature on August 1, 2026. $500.0 Million Unsecured Senior Notes due 2027 In 2017, HTALP issued $500.0 million of unsecured senior notes that are guaranteed by HTA. These unsecured senior notes are registered under the Securities Act, and bear interest at 3.75% per annum which is payable semi-annually. Additionally, these unsecured senior notes were offered at 99.49% of the principal amount thereof, with an effective yield to maturity of 3.81% per annum. As of June 30, 2022, we had $500.0 million of these unsecured senior notes outstanding that mature on July 1, 2027. $650.0 million Unsecured Senior Notes due 2030 In September 2019, in connection with the $250.0 million additional unsecured senior notes due 2026 referenced above, HTALP issued $650.0 million of unsecured senior notes that are guaranteed by HTA. These unsecured senior notes are registered under the Securities Act, and bear interest at 3.10% per annum which is payable semi-annually. Additionally, these unsecured senior notes were offered at 99.66% of the principal amount thereof, with an effective yield to maturity of 3.14% per annum. Proceeds from the issuance of $900.0 million of these notes were used, in part, to redeem a total of $700.0 million of unsecured senior notes. During the year ended December 31, 2019, the make-whole fees required per the terms of the indenture agreements upon our calling the notes totaling $18.3 million was recorded in loss on extinguishment of debt in the accompanying consolidated statements of operations. As of June 30, 2022, HTALP had $650.0 million of these unsecured senior notes outstanding that mature on February 15, 2030. $800.0 million Unsecured Senior Notes due 2031 In September 2020, HTALP issued $800.0 million of unsecured senior notes that are guaranteed by HTA. These unsecured senior notes are registered under the Securities Act, and bear interest at 2.00% per annum which is payable semi-annually. Additionally, these unsecured senior notes were offered at 99.20% of the principal amount thereof, with an effective yield to maturity of 2.09% per annum. We incurred financing costs of $6.8 million in relation to this transaction, which are being amortized through the maturity date. Proceeds from the issuance of these unsecured notes were used, in part, to redeem $300.0 million of unsecured senior notes. During the year ended December 31, 2020, the make-whole fee that was required per the terms of the indenture agreement upon our calling the notes of $24.7 million was recorded in loss on extinguishment of debt in the accompanying consolidated statements of operations. As of June 30, 2022, we had $800.0 million of these unsecured senior notes outstanding that mature on March 15, 2031. Future Debt Maturities The following table summarizes the debt maturities and scheduled principal repayments of our indebtedness as of June 30, 2022 (in thousands): Year Amount 2022 $ — 2023 — 2024 200,000 2025 365,000 2026 600,000 Thereafter 1,950,000 Total $ 3,115,000 Deferred Financing Costs In February 2022, as part of the $1.7 billion bridge financing commitment secured in connection with the Merger, we incurred commitment fees of approximately $5.4 million. In May 2022, this financing commitment was replaced with a $1.125 billion unsecured Term Loan Facility (see above for more details of this transaction) with the remaining unamortized commitment fees written off, causing a loss on extinguishment of debt of $3.6 million. With the new Term Loan Facility we incurred approximately $1.8 million in financing costs, which will be amortized through the expiration date of May 13, 2023. As of June 30, 2022, the future amortization of our deferred financing costs is as follows (in thousands): Year Amount 2022 $ 1,554 2023 3,107 2024 2,725 2025 2,604 2026 1,839 Thereafter 4,597 Total $ 16,426 Debt Covenants

Derivative Financial Instrument

Derivative Financial Instruments and Hedging Activities	6 Months Ended
	Jun. 30, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Financial Instruments and Hedging Activities	Derivative Financial Instruments and Hedging Activities Risk Management Objective of Using Derivative Financial Instruments We may use derivative financial instruments, including interest rate swaps, caps, options, floors and other interest rate derivative contracts, to hedge all or a portion of the interest rate risk associated with our borrowings. The principal objective of such arrangements is to minimize the risks and/or costs associated with our operating and financial structure as well as to hedge specific anticipated transactions. We do not intend to utilize derivatives for speculative or other purposes other than interest rate risk management. The use of derivative financial instruments carries certain risks, including the risk that the counterparties to these contractual arrangements are not able to perform under the agreements. To mitigate this risk, we only enter into derivative financial instruments with counterparties with high credit ratings and with major financial institutions with which we and our affiliates may also have other financial relationships. We do not anticipate that any of the counterparties will fail to meet their obligations. We record counterparty credit risk valuation adjustments on interest rate swap derivative assets in order to properly reflect the credit quality of the counterparty. In addition, the fair value of derivative financial instruments designated as cash flow hedges are adjusted to reflect the impact of our credit quality. Cash Flow Hedges of Interest Rate Risk Our objectives in using interest rate derivatives are to add stability to interest expense and to manage our exposure to interest rate movements. To accomplish this objective, we primarily use interest rate swaps and treasury locks as part of our interest rate risk management strategy. Interest rate swaps designated as cash flow hedges involve the receipt of variable rate amounts from a counterparty in exchange for us making fixed rate payments over the life of the agreements without an exchange of the underlying notional amount. A treasury lock is a synthetic forward sale of a U.S. treasury note, which is settled in cash based upon the difference between an agreed upon treasury rate and the prevailing treasury rate at settlement. Such treasury locks are entered into to effectively fix the treasury component of an upcoming debt issuance. Amounts reported in accumulated other comprehensive income in the accompanying condensed consolidated balance sheets related to derivatives will be reclassified to interest expense as interest payments are made on our variable rate debt. During the next twelve months, we estimate that an additional $5.6 million will be reclassified from other comprehensive income in the accompanying condensed consolidated balance sheets as an increase to interest related to derivative financial instruments in the accompanying condensed consolidated statements of operations. As of June 30, 2022, we had the following outstanding interest rate derivatives that were designated as cash flow hedges of interest rate risk (in thousands, except number of instruments): Interest Rate Swaps June 30, 2022 Number of instruments 7 Notional amount $ 500,000 The table below presents the fair value of our derivative financial instruments designated as cash flow hedges as well as the classification in the accompanying condensed consolidated balance sheets as of June 30, 2022 and December 31, 2021, respectively (in thousands): Asset Derivatives Liability Derivatives Fair Value at: Fair Value at: Derivatives Designated as Hedging Instruments: Balance Sheet June 30, 2022 December 31, 2021 Balance Sheet June 30, 2022 December 31, 2021 Interest rate swaps Receivables and other assets $ 7,721 $ — Derivative financial instruments $ — $ 5,069 The table below presents the gain or loss recognized on our derivative financial instruments designated as cash flow hedges as well as the classification in the accompanying condensed consolidated statements of operations for the three and six months ended June 30, 2022 and 2021, respectively (in thousands): Three Months Ended June 30, Six Months Ended June 30, Effect of Derivative Instruments Location in Statement of Operations and Comprehensive Income (Loss) 2022 2021 2022 2021 Gain (loss) recognized in OCI Change in unrealized losses on cash flow hedges $ 3,255 $ (150) $ 10,473 $ 1,013 Gain (loss) reclassified from accumulated OCI into income Interest expense (830) (1,673) (2,429) (3,302) Credit Risk Related Contingent Features We have agreements with each of our derivative counterparties that contain a provision that if we default on any of our indebtedness, including a default where repayment of the indebtedness has not been accelerated by the lender, then we could also be declared in default on our derivative obligations. We also have agreements with each of our derivative counterparties that incorporate provisions from our indebtedness with a lender affiliate of the derivative counterparty requiring it to maintain certain minimum financial covenant ratios on our indebtedness. Failure to comply with the covenant provisions would result in us being in default on any derivative instrument obligations covered by these agreements.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Litigation Two purported stockholders of HTA filed actions in the United States District Court for the Southern District of New York captioned Stein v. Healthcare Trust of America, Inc. , Case No. No. 1:22cv-03703 (S.D.N.Y.), and Tiso v. Healthcare Trust of America, Inc. , Case No. 1:22CV03804 (S.D.N.Y.), alleging that the Registration Statement on Form S-4 filed by the Company with the SEC on May 2, 2022, which included the Preliminary Proxy Statement, was materially incomplete, false or misleading in certain respects, thereby allegedly violating Sections 14(a) and 20(a) of the Exchange Act (15 U.S.C. § § 78n(a), 78t(a)), and SEC Rule 14a-9 (17 C.F.R. § 240.14a-9) or 17 C.F.R. § 244.100 promulgated thereunder. In addition, a purported shareholder filed an action in the United States District Court for the Eastern District of New York, captioned Johnson v. Healthcare Trust of America, Inc. , Case No. 1:22-cv-03692 (E.D.N.Y.), which generally alleged that the Definitive Proxy Statement filed by HR on June 10, 2022 failed to disclose material information in connection with the Merger and that, as a result, the Definitive Proxy Statement is materially misleading in violation of Section 14(a) and Section 20(a) of the Exchange Act. These three actions collectively are referred to as the “Complaints”. Each of the Complaints had sought, among other things, to enjoin the Company and HR from consummating the Merger or, in the alternative, rescission of the Merger or damages. Although the Company believed that the claims asserted in the Complaints were without merit and that no supplemental disclosure was required under applicable law, in order to avoid the risk of the above actions delaying or adversely affecting the Merger, to alleviate the costs, risks and uncertainties inherent in litigation, to provide additional information to its stockholders, and without admitting any liability or wrongdoing, the Company voluntarily supplemented the Definitive Proxy Statement, and these Complaints have since been settled. Additional lawsuits may be filed against us, our Board of Directors, and/or other parties to the Merger in connection with the transactions contemplated by the Merger Agreement. In addition, we are, from time to time, also subject to claims and litigation arising in the ordinary course of business with respect to tenant litigation and threatened or asserted labor matters. We do not believe liability from any reasonably foreseeable disposition of the aforementioned claims and litigation, individually or in the aggregate, would have a material effect on our consolidated financial position, results of operations or cash flows. Environmental Matters We routinely monitor our properties for the presence of hazardous or toxic substances. While there can be no assurance that a material environmental liability does not exist at our properties, we are not currently aware of any environmental liability with respect to our properties that would have a material effect on our condensed consolidated financial position, results of operations or cash flows. Further, we are not aware of any material environmental liability or any unasserted claim or assessment with respect to an environmental liability at our properties that we believe would require additional disclosure or the recording of a loss contingency. Other Our other commitments and contingencies include the usual obligations of real estate owners and operators in the normal course of business. In our opinion, these matters are not expected to have a material adverse effect on our condensed consolidated financial position, results of operations or cash flows.

Stockholders' Equity and Partne

Stockholders' Equity and Partners' Capital	6 Months Ended
	Jun. 30, 2022
Equity [Abstract]
Stockholders' Equity and Partners' Capital	Stockholders’ Equity and Partners’ CapitalHTALP’s operating partnership agreement provides that it will distribute cash flow from operations and net sale proceeds to its partners in accordance with their overall ownership interests at such times and in such amounts as the general partner thereof determines. Dividend distributions are made such that a holder of one OP Unit in HTALP will receive distributions from HTALP in an amount equal to the dividend distributions paid to the holder of one share of our common stock. In addition, for each share of common stock issued or redeemed by HTA, HTALP issues or redeems a corresponding number of OP Units. Common Stock Offerings In March 2021, we entered into equity distribution agreements with various sales agents with respect to our at-the-market (“ATM”) offering program of common stock with an aggregate sales amount of up to $750.0 million, which replaced our prior ATM offering program that expired in February 2021. As of June 30, 2022, $750.0 million remained available for issuance by us under our current ATM. Stock Repurchase Plan In September 2020, our Board of Directors approved the reactivation of a stock repurchase plan authorizing us to purchase up to $300.0 million of our common stock from time to time prior to the expiration thereof on September 22, 2023. As of June 30, 2022, the remaining amount of common stock available for repurchase under our stock repurchase plan was $300.0 million. Common Stock Dividends See our accompanying condensed consolidated statements of equity and condensed statements of changes in partners’ capital for the dividends declared during the three and six months ended June 30, 2022 and 2021. As of June 30, 2022, declared, but unpaid, dividends totaling $75.8 million were included in accounts payable and accrued liabilities. On July 1, 2022, our Board of Directors announced a pro-rata quarterly dividend of $0.029 per share of common stock and per OP Unit to be paid on July 19, 2022 to stockholders and unitholders of record on July 14, 2022. On July 6, 2022, our Board of Directors announced a special distribution of $4.82 per share of common stock and per OP Unit pursuant to the Merger Agreement to be paid on July 27, 2022 to stockholders and unitholders of record on July 19, 2022. Incentive Plan Our Incentive Plan permits the grant of incentive awards to our employees, officers, non-employee directors and consultants as selected by our Board of Directors. This Plan authorizes us to grant awards in any of the following forms: options; stock appreciation rights; restricted stock; restricted or deferred stock units; performance awards; dividend equivalents; other stock-based awards, including units in HTALP; and cash-based awards. Subject to adjustment as provided in the Plan, the aggregate number of awards reserved and available for issuance under the Plan is 10,000,000 shares. As of June 30, 2022, there were 9,647,839 awards available for grant under the Plan. Restricted Common Stock We recognized compensation expense, equal to the fair market value of HTA’s stock on the grant date, over the service period which is generally three As of June 30, 2022, we had $6.2 million of unrecognized compensation expense, net of estimated forfeitures, which we will recognize over a remaining weighted average period of 1.6 years. The following is a summary of our restricted common stock activity as of June 30, 2022 and 2021, respectively: June 30, 2022 June 30, 2021 Restricted Common Stock Weighted Restricted Common Stock Weighted Beginning balance 529,862 $ 28.83 436,399 $ 28.27 Granted 158,543 30.81 354,288 26.62 Vested (124,407) 27.37 (270,099) 27.48 Forfeited (7,690) 29.58 (6,767) 28.87 Ending balance 556,308 $ 29.71 513,821 $ 27.54

Fair Value of Financial Instrum

Fair Value of Financial Instruments	6 Months Ended
	Jun. 30, 2022
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	Fair Value of Financial Instruments Financial Instruments Reported at Fair Value - Recurring The table below presents the carrying amounts and fair values of our financial instruments on a recurring basis as of June 30, 2022 and December 31, 2021, respectively (in thousands): June 30, 2022 December 31, 2021 Carrying Amount Fair Value Carrying Amount Fair Value Level 2 - Assets: Real estate notes receivable, net $ 75,872 $ 72,377 $ 69,114 $ 68,476 Derivative financial instruments 7,721 7,721 — — Level 2 - Liabilities: Derivative financial instruments $ — $ — $ 5,069 $ 5,069 Debt 3,094,643 2,797,099 3,028,122 3,117,602 The carrying amounts of cash and cash equivalents, tenant and other receivables, restricted cash, accounts payable, and accrued liabilities approximate fair value. There have been no transfers of assets or liabilities between levels. We will record any such transfers at the end of the reporting period in which a change of event occurs that results in a transfer. Although we have determined that the majority of the inputs used to value our cash flow hedges fall within Level 2 of the fair value hierarchy, the credit valuation adjustments associated with these instruments utilize Level 3 inputs, such as estimates of current credit spreads to evaluate the likelihood of default by us and our counterparties. However, we have assessed the significance of the impact of the credit valuation adjustments on the overall valuation of our cash flow hedge positions and have determined that the credit valuation adjustments are not significant to their overall valuation. As a result, we have determined that our cash flow hedge valuations in their entirety are classified in Level 2 of the fair value hierarchy. For further discussion of the assumptions considered, refer to Note 2 - Summary of Significant Accounting Policies. Financial Instruments Reported at Fair Value - Non-Recurring We also have assets that under certain conditions are subject to measurement at fair value on a non-recurring basis. This category generally includes assets subject to impairment. We estimate fair value relating to impairment assessments based upon discounted cash flow and direct capitalization models that include all projected cash inflows and outflows over a specific holding period, or the contractual sales price, if applicable. Such projected cash flows are comprised of contractual rental revenues and forecasted rental revenues and expenses based on market conditions and expectations for growth. Capitalization rates and discount rates utilized in these models are based on a reasonable range of current market rates for each property analyzed. Based on these inputs, we determined that our valuation of properties using a discounted cash flow or a direct capitalization model were classified within Level 3 of the fair value hierarchy. For assets for which the estimated fair value was based on contractual sales prices, we determined that our valuation was classified within Level 2 of the fair value hierarchy. As of June 30, 2022 we had no assets subject to impairment. The table below presents our assets measured at fair value on a non-recurring basis as of June 30, 2022 and December 31, 2021 (in thousands): June 30, 2022 December 31, 2021 Fair Value Fair Value Level 2 - Assets: Real estate investment $ — $ 26,768 Level 3 - Assets: Real estate investments $ — $ 4,970

Per Share Data of HTA

Per Share Data of HTA	6 Months Ended
	Jun. 30, 2022
Earnings Per Share [Abstract]
Per Share Data of HTA	Per Share Data of HTA For the three and six months ended June 30, 2022 and 2021, all of our earnings were distributed and the calculated earnings per share amount would be the same for all classes. The following is the reconciliation of the numerator and denominator used in basic and diluted earnings per share of HTA for the three and six months ended June 30, 2022 and 2021, respectively (in thousands, except per share data): Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Numerator: Net income $ 14,422 $ 38,739 $ 33,088 $ 61,132 Net income attributable to non-controlling interests (254) (728) (605) (1,091) Net income attributable to common stockholders $ 14,168 $ 38,011 $ 32,483 $ 60,041 Denominator: Weighted average shares outstanding - basic 229,074 218,822 229,026 218,787 Dilutive shares - OP Units convertible into common stock 4,051 3,504 4,060 3,510 Adjusted weighted average shares outstanding - diluted 233,125 222,326 233,086 222,297 Earnings per common share - basic Net income attributable to common stockholders $ 0.06 $ 0.17 $ 0.14 $ 0.27 Earnings per common share - diluted Net income attributable to common stockholders $ 0.06 $ 0.17 $ 0.14 $ 0.27

Per Unit Data of HTALP

Per Unit Data of HTALP	6 Months Ended
	Jun. 30, 2022
Earnings Per Share
Per Unit Data of HTALP	Per Share Data of HTA For the three and six months ended June 30, 2022 and 2021, all of our earnings were distributed and the calculated earnings per share amount would be the same for all classes. The following is the reconciliation of the numerator and denominator used in basic and diluted earnings per share of HTA for the three and six months ended June 30, 2022 and 2021, respectively (in thousands, except per share data): Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Numerator: Net income $ 14,422 $ 38,739 $ 33,088 $ 61,132 Net income attributable to non-controlling interests (254) (728) (605) (1,091) Net income attributable to common stockholders $ 14,168 $ 38,011 $ 32,483 $ 60,041 Denominator: Weighted average shares outstanding - basic 229,074 218,822 229,026 218,787 Dilutive shares - OP Units convertible into common stock 4,051 3,504 4,060 3,510 Adjusted weighted average shares outstanding - diluted 233,125 222,326 233,086 222,297 Earnings per common share - basic Net income attributable to common stockholders $ 0.06 $ 0.17 $ 0.14 $ 0.27 Earnings per common share - diluted Net income attributable to common stockholders $ 0.06 $ 0.17 $ 0.14 $ 0.27
Healthcare Trust of America Holdings, LP (HTALP)
Earnings Per Share
Per Unit Data of HTALP	Per Unit Data of HTALP The following is the reconciliation of the numerator and denominator used in basic and diluted earnings per unit of HTALP for the three and six months ended June 30, 2022 and 2021, respectively (in thousands, except per unit data): Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Numerator: Net income $ 14,422 $ 38,739 $ 33,088 $ 61,132 Net income attributable to non-controlling interests — — — — Net income attributable to common unitholders $ 14,422 $ 38,739 $ 33,088 $ 61,132 Denominator: Weighted average OP Units outstanding - basic 233,125 222,326 233,086 222,297 Dilutive units - OP Units convertible into common units — — — — Adjusted weighted average units outstanding - diluted 233,125 222,326 233,086 222,297 Earnings per common unit - basic: Net income attributable to common unitholders $ 0.06 $ 0.17 $ 0.14 $ 0.28 Earnings per common unit - diluted: Net income attributable to common unitholders $ 0.06 $ 0.17 $ 0.14 $ 0.28

Supplemental Cash Flow Informat

Supplemental Cash Flow Information	6 Months Ended
	Jun. 30, 2022
Supplemental Cash Flow Elements [Abstract]
Supplemental Cash Flow Information	Supplemental Cash Flow Information The following is the supplemental cash flow information for the six months ended June 30, 2022 and 2021, respectively (in thousands): Six Months Ended June 30, 2022 2021 Supplemental Disclosure of Cash Flow Information: Interest paid, net of capitalized interest $ 50,284 $ 39,827 Cash paid for operating leases 7,609 7,942 Supplemental Disclosure of Noncash Investing and Financing Activities: Accrued capital expenditures $ 6,244 $ 13,065 Dividend distributions declared, but not paid 75,765 71,302 Redemption of non-controlling interest 2,065 546 ROU assets obtained in exchange for lease obligations 705 7,683

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Basis of Presentation	Our accompanying condensed consolidated financial statements include our accounts and those of our subsidiaries and any consolidated variable interest entities (“VIEs”). All inter-company balances and transactions have been eliminated in the accompanying condensed consolidated financial statements.
Principles of Consolidation	The condensed consolidated financial statements include the accounts of our subsidiaries and consolidated joint venture arrangements. The portions of the HTALP operating partnership not owned by us are presented as non-controlling interests on the accompanying condensed consolidated balance sheets and statements of operations, condensed consolidated statements of comprehensive income, and condensed consolidated statements of equity and changes in partners’ capital. Holders of OP Units are considered to be non-controlling interest holders in HTALP and their ownership interests are reflected as equity on the accompanying condensed consolidated balance sheets. Further, a portion of the earnings and losses of HTALP are allocated to non-controlling interest holders based on their respective ownership percentages. Upon conversion of OP Units to common stock, any difference between the fair value of the common stock issued and the carrying value of the OP Units converted to common stock is recorded as a component of equity. As of both June 30, 2022 and December 31, 2021, there were approximately 4.1 million of OP Units issued and outstanding held by non-controlling interest holders.VIEs are entities where investors lack sufficient equity at risk for the entity to finance its activities without additional subordinated financial support or where equity investors, as a group, lack one of the following: (i) the power to direct the activities that most significantly impact the entity’s economic performance; (ii) the obligation to absorb the expected losses of the entity; and (iii) the right to receive the expected returns of the entity. We consolidate our investment in VIEs when we determine that we are the primary beneficiary. A primary beneficiary is one that has both: (i) the power to direct the activities of the VIE that most significantly impacts the entity’s economic performance; and (ii) the obligation to absorb losses or the right to receive benefits of the VIE that could be significant to the entity. The HTALP operating partnership and our other joint venture arrangements are VIEs because the limited partners in those partnerships, although entitled to vote on certain matters, do not possess kick-out rights or substantive participating rights. Additionally, we determined that we are the primary beneficiary of our VIEs. Accordingly, we consolidate our interests in the HTALP operating partnership and in our other joint venture arrangements. However, because we hold what is deemed a majority voting interest in the HTALP operating partnership and our other joint venture arrangements, it qualifies for the exemption from providing certain disclosure requirements associated with investments in VIEs.
Use of Estimates	The preparation of our condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that effect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent asset and liabilities. These estimates are made and evaluated on an ongoing basis using information that is currently available as well as various other assumptions believed to be reasonable under the circumstances. Actual results could differ from those estimates, perhaps in adverse ways, and those estimates could be different under different assumptions or conditions.
Cash, Cash Equivalents and Restricted Cash	Cash and cash equivalents consist of all highly liquid investments with a maturity of three months or less when purchased. Restricted cash is typically comprised of: (i) reserve accounts for property taxes, insurance, capital and tenant improvements; (ii) collateral accounts for debt and interest rate swaps; (iii) 1031 exchange funds; and (iv) deposits for future investments.
Revenue Recognition	Minimum annual rental revenue is recognized on a straight-line basis over the term of the related lease (including rent holidays). Differences between rental income recognized and amounts contractually due under the lease agreements are recorded as straight-line rent receivables. Tenant reimbursements, which is comprised of additional amounts recoverable from tenants for real estate taxes, common area maintenance and other certain operating expenses are recognized as revenue on a gross basis in the period in which the related recoverable expenses are incurred.  We accrue revenue corresponding to these expenses on a quarterly basis to adjust recorded amounts to our best estimate of the final annual amounts to be billed. Subsequent to year-end, on a calendar year basis, we perform reconciliations on a lease-by-lease basis and bill or credit each tenant for any differences between the estimated expenses we billed and the actual expenses that were incurred. We recognize lease termination fees when there is a signed termination letter agreement, all of the conditions of the agreement have been met, and the tenant is no longer occupying the property. Rental income is reported net of amortization of inducements. The revenue recognition process is based on a five-step model to account for revenue arising from contracts with customers as outlined in ASC Topic 606 - Revenue from Contracts with Customers. We recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. We have identified all of our revenue streams and we have concluded that rental income from leasing arrangements represents a substantial portion of our revenue and is governed and evaluated with the adoption of ASC Topic 842 - Lessors - Certain Leases with Variable Lease Payments (“Topic 842”).
Leases	As a lessor, we lease space in our MOBs primarily to medical enterprises for terms generally ranging from three
Leases	Leases, for which we are the lessee, are classified as separate components on our accompanying condensed consolidated balance sheets. Operating leases are included as right-of-use (“ROU”) assets - operating leases, net, with a corresponding lease liability. Financing lease assets are included in receivables and other assets, net, with a corresponding lease liability in security deposits, prepaid rent and other liabilities. A lease liability is recognized for our obligation related to the lease and an ROU asset represents our right to use the underlying asset over the lease term. Refer to Note 7 - Leases in the accompanying notes to the condensed consolidated financial statements for more detail relating to our leases.
Real Estate Held for Sale	We consider properties held for sale once management commits to a plan to sell the property and has determined that the sale is probable and expected to occur within one year. Upon classification as held for sale, we record the property at the lower of its carrying amount or fair value, less costs to sell, and cease depreciation and amortization. The fair value is generally based on a discounted cash flow analysis, which involves management's best estimate of market participants' holding periods, market comparables, future occupancy levels, rental rates, capitalization rates, lease-up periods and capital requirements.
Real Estate Notes Receivable	Real estate notes receivable consists of mezzanine and other real estate loans, which are generally collateralized by a pledge of the borrower’s ownership interest in the respective real estate owner and/or corporate guarantees . Real estate notes receivable are intended to be held-to-maturity and are recorded at amortized cost, net of unamortized loan origination costs and fees and allowance for credit losses. As of June 30, 2022, real estate notes receivable, net totaled $75.9 million. During the six months ended June 30, 2022, we recognized interest income of $3.2 million related to real estate notes receivable. The following table summarizes real estate notes receivable as of June 30, 2022 (in thousands): Stated Interest Rate Maximum Loan Commitment Outstanding Loan Amount Origination Date Maturity Date June 30, 2022 Mezzanine Loans - Texas (1) 6/24/2021 6/24/2024 8 % $ 54,119 $ 53,756 Mezzanine Loan - North Carolina 12/22/2021 12/22/2024 8 % 6,000 6,000 Mortgage Loan - Texas 6/30/2021 7/1/2022 10 % 15,000 15,000 Construction Loan - Florida 5/17/2022 2/27/2026 6 % 65,000 1,464 76,220 Accrued interest receivable 311 Unamortized fees and costs (659) Unearned revenue — $ 75,872 (1) Interest on these mezzanine loans is accrued and funded utilizing interest reserves, which is included in the maximum loan commitment, and such accrued interest is added to the note receivable balance. Pursuant to ASC Topic 326 - Financial Instruments - Credit Losses ( “Topic 326”)
Unconsolidated Joint Ventures	We account for our investments in unconsolidated joint ventures using the equity method of accounting because we have the ability to exercise significant influence, but not control, over the financial and operational policy decisions of the investments. Using the equity method of accounting, the initial investment is recognized at cost and subsequently adjusted for our share of the net income and any distributions from the joint venture.
Recently Issued or Adopted Accounting Pronouncements	Recently Issued or Adopted Accounting Pronouncements Recently Adopted Accounting Pronouncements ASU 2021-05, Leases (Topic 842): Lessors - Certain Leases with Variable Lease Payments In July 2021, the FASB issued ASU 2021-05, which amends the lease classification requirements for lessors when classifying and accounting for a lease with variable lease payments that do not depend on a reference index or a rate. The update provides criteria, that if met, the lease would be classified and accounted for as an operating lease. The update is effective for reporting periods beginning after December 15, 2021, with early adoption permitted. We adopted ASU 2021-05 effective as of January 1, 2022. The adoption of this standard did not have a material impact on our financial statements. Recently Issued Accounting Pronouncements ASU 2021-01, Reference Rate Reform (Topic 848) In January 2021, the FASB issued ASU 2021-01, which amends the scope of ASU 2020-04. The amendments of ASU 2021-01 clarify that certain optional expedients and exceptions to Topic 848 for contract modification and hedge accounting apply to derivatives that are affected by the discounting transition. For information related to the Company's current cash flow hedges, refer to Note 9 - Derivative Financial Instruments and Hedging Activities. The amendments are elective and effective immediately for contract modifications made through December 31, 2022. We do not expect that this ASU will have a material impact on our financial statements.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Schedule of Cash and Cash Equivalents	The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the accompanying condensed consolidated balance sheets to the combined amounts shown on the accompanying condensed consolidated statements of cash flows (in thousands): June 30, 2022 2021 Cash and cash equivalents $ 29,714 $ 19,796 Restricted cash 4,559 70,542 Total cash, cash equivalents and restricted cash $ 34,273 $ 90,338
Schedule of Restricted Cash	The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the accompanying condensed consolidated balance sheets to the combined amounts shown on the accompanying condensed consolidated statements of cash flows (in thousands): June 30, 2022 2021 Cash and cash equivalents $ 29,714 $ 19,796 Restricted cash 4,559 70,542 Total cash, cash equivalents and restricted cash $ 34,273 $ 90,338
Schedule of Real Estate Held For Sale	The following table summarizes real estate notes receivable as of June 30, 2022 (in thousands): Stated Interest Rate Maximum Loan Commitment Outstanding Loan Amount Origination Date Maturity Date June 30, 2022 Mezzanine Loans - Texas (1) 6/24/2021 6/24/2024 8 % $ 54,119 $ 53,756 Mezzanine Loan - North Carolina 12/22/2021 12/22/2024 8 % 6,000 6,000 Mortgage Loan - Texas 6/30/2021 7/1/2022 10 % 15,000 15,000 Construction Loan - Florida 5/17/2022 2/27/2026 6 % 65,000 1,464 76,220 Accrued interest receivable 311 Unamortized fees and costs (659) Unearned revenue — $ 75,872 (1) Interest on these mezzanine loans is accrued and funded utilizing interest reserves, which is included in the maximum loan commitment, and such accrued interest is added to the note receivable balance.

Investments in Real Estate (Tab

Investments in Real Estate (Tables)	6 Months Ended
	Jun. 30, 2022
Investments [Abstract]
Schedule of Purchase Price Allocation	The allocations for these investments, in which we own a controlling financial interest, are set forth below in the aggregate for the six months ended June 30, 2022 and 2021, respectively (in thousands): Six Months Ended June 30, 2022 2021 Land $ 3,812 $ 1,093 Building and improvements 19,761 45,629 In place leases 2,121 5,291 Below market leases (28) (79) Above market leases — 66 ROU assets — (1,372) Net real estate assets acquired 25,666 50,628 Other, net — 2,397 Aggregate purchase price $ 25,666 $ 53,025
Schedule of Weighted Average Lives of Acquired Intangible Assets and Liabilities	The acquired intangible assets and liabilities referenced above had weighted average lives of the following terms for the six months ended June 30, 2022 and 2021, respectively (in years): Six Months Ended June 30, 2022 2021 Acquired intangible assets 4.2 4.2 Acquired intangible liabilities 4.1 5.7

Intangible Assets and Liabili_2

Intangible Assets and Liabilities (Tables)	6 Months Ended
	Jun. 30, 2022
Identified Intangibles, Net [Abstract]
Schedule of Intangible Assets and Liabilities	Intangible assets and liabilities consisted of the following as of June 30, 2022 and December 31, 2021, respectively (in thousands, except with respect to the weighted average remaining amortization terms): June 30, 2022 December 31, 2021 Balance Weighted Average Remaining Balance Weighted Average Remaining Assets: In place leases $ 334,807 9.3 $ 349,863 9.3 Tenant relationships 47,931 10.9 54,851 10.8 Above market leases 20,548 6.8 21,537 6.9 403,286 426,251 Accumulated amortization (210,279) (213,801) Total $ 193,007 9.3 $ 212,450 9.3 Liabilities: Below market leases $ 53,695 14.6 $ 55,073 14.3 Accumulated amortization (25,024) (23,742) Total $ 28,671 14.6 $ 31,331 14.3
Summary of Net Intangible Amortization	The following is a summary of the net intangible amortization for the three and six months ended June 30, 2022 and 2021, respectively (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Amortization recorded against rental income related to above and (below) market leases $ (634) $ (641) $ (1,283) $ (1,233) Amortization expense related to in place leases and tenant relationships 9,843 11,340 20,159 23,227

Receivables and Other Assets (T

Receivables and Other Assets (Tables)	6 Months Ended
	Jun. 30, 2022
Receivables and Other Assets [Abstract]
Schedule of Receivables and Other Assets	Receivables and other assets consisted of the following as of June 30, 2022 and December 31, 2021, respectively (in thousands): June 30, 2022 December 31, 2021 Tenant receivables, net $ 10,131 $ 10,477 Other receivables, net 10,335 6,098 Deferred financing costs, net 7,697 7,055 Deferred leasing costs, net 48,418 45,008 Straight-line rent receivables, net 149,602 142,604 Prepaid expenses, deposits, equipment and other, net 34,549 38,301 Derivative financial instruments - interest rate swaps 7,721 — Real estate notes receivable, net 75,872 69,114 Finance ROU asset, net 16,108 16,284 Total $ 360,433 $ 334,941
Summary of Amortization of Deferred Leasing Costs and Deferred Financing Costs	The following is a summary of the amortization of deferred leasing costs and financing costs for the three and six months ended June 30, 2022 and 2021, respectively (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Amortization expense related to deferred leasing costs $ 2,296 $ 2,204 $ 4,523 $ 4,427 Interest expense related to deferred financing costs 1,560 431 2,913 862

Leases (Tables)

Leases (Tables)	6 Months Ended
	Jun. 30, 2022
Leases [Abstract]
Summary of lease repayments of operating lease liabilities	The following table summarizes the future minimum lease obligations of our operating and finance leases as of June 30, 2022 (in thousands): Year Operating Leases Finance Leases 2022 $ 5,378 $ 316 2023 10,884 635 2024 10,411 640 2025 9,899 645 2026 9,901 656 2027 9,886 668 Thereafter 591,325 36,856 Total undiscounted lease payments $ 647,684 $ 40,416 Less: Interest (450,693) (23,506) Present value of lease liabilities $ 196,991 $ 16,910
Schedule of undiscounted cash flows for future minimum rents	The following table summarizes the future minimum rent contractually due under operating leases, excluding tenant reimbursements of certain costs, as of June 30, 2022 (in thousands): Year Amount 2022 $ 290,284 2023 551,493 2024 495,354 2025 436,400 2026 388,471 2027 318,837 Thereafter 1,345,024 Total $ 3,825,863

Debt (Tables)

Debt (Tables)	6 Months Ended
	Jun. 30, 2022
Debt Disclosure [Abstract]
Schedule of Debt	Debt consisted of the following as of June 30, 2022 and December 31, 2021, respectively (in thousands): June 30, 2022 December 31, 2021 Unsecured revolving credit facility $ 65,000 $ — Unsecured term loans 500,000 500,000 Unsecured senior notes 2,550,000 2,550,000 Fixed rate mortgages — — $ 3,115,000 $ 3,050,000 Deferred financing costs, net (16,426) (17,975) Discount, net (3,931) (3,903) Total $ 3,094,643 $ 3,028,122
Summary of Debt Maturities and Scheduled Principal Debt Repayments	The following table summarizes the debt maturities and scheduled principal repayments of our indebtedness as of June 30, 2022 (in thousands): Year Amount 2022 $ — 2023 — 2024 200,000 2025 365,000 2026 600,000 Thereafter 1,950,000 Total $ 3,115,000
Schedule of Amortization of Deferred Financing Costs	As of June 30, 2022, the future amortization of our deferred financing costs is as follows (in thousands): Year Amount 2022 $ 1,554 2023 3,107 2024 2,725 2025 2,604 2026 1,839 Thereafter 4,597 Total $ 16,426

Derivative Financial Instrume_2

Derivative Financial Instruments and Hedging Activities (Tables)	6 Months Ended
	Jun. 30, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Interest Rate Derivatives	As of June 30, 2022, we had the following outstanding interest rate derivatives that were designated as cash flow hedges of interest rate risk (in thousands, except number of instruments): Interest Rate Swaps June 30, 2022 Number of instruments 7 Notional amount $ 500,000 The table below presents the fair value of our derivative financial instruments designated as cash flow hedges as well as the classification in the accompanying condensed consolidated balance sheets as of June 30, 2022 and December 31, 2021, respectively (in thousands): Asset Derivatives Liability Derivatives Fair Value at: Fair Value at: Derivatives Designated as Hedging Instruments: Balance Sheet June 30, 2022 December 31, 2021 Balance Sheet June 30, 2022 December 31, 2021 Interest rate swaps Receivables and other assets $ 7,721 $ — Derivative financial instruments $ — $ 5,069 The table below presents the gain or loss recognized on our derivative financial instruments designated as cash flow hedges as well as the classification in the accompanying condensed consolidated statements of operations for the three and six months ended June 30, 2022 and 2021, respectively (in thousands): Three Months Ended June 30, Six Months Ended June 30, Effect of Derivative Instruments Location in Statement of Operations and Comprehensive Income (Loss) 2022 2021 2022 2021 Gain (loss) recognized in OCI Change in unrealized losses on cash flow hedges $ 3,255 $ (150) $ 10,473 $ 1,013 Gain (loss) reclassified from accumulated OCI into income Interest expense (830) (1,673) (2,429) (3,302)

Stockholders' Equity and Part_2

Stockholders' Equity and Partners' Capital (Tables)	6 Months Ended
	Jun. 30, 2022
Equity [Abstract]
Schedule of Restricted Common Stock Activity	The following is a summary of our restricted common stock activity as of June 30, 2022 and 2021, respectively: June 30, 2022 June 30, 2021 Restricted Common Stock Weighted Restricted Common Stock Weighted Beginning balance 529,862 $ 28.83 436,399 $ 28.27 Granted 158,543 30.81 354,288 26.62 Vested (124,407) 27.37 (270,099) 27.48 Forfeited (7,690) 29.58 (6,767) 28.87 Ending balance 556,308 $ 29.71 513,821 $ 27.54

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	6 Months Ended
	Jun. 30, 2022
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	The table below presents the carrying amounts and fair values of our financial instruments on a recurring basis as of June 30, 2022 and December 31, 2021, respectively (in thousands): June 30, 2022 December 31, 2021 Carrying Amount Fair Value Carrying Amount Fair Value Level 2 - Assets: Real estate notes receivable, net $ 75,872 $ 72,377 $ 69,114 $ 68,476 Derivative financial instruments 7,721 7,721 — — Level 2 - Liabilities: Derivative financial instruments $ — $ — $ 5,069 $ 5,069 Debt 3,094,643 2,797,099 3,028,122 3,117,602
Fair Value Measurements, Nonrecurring	The table below presents our assets measured at fair value on a non-recurring basis as of June 30, 2022 and December 31, 2021 (in thousands): June 30, 2022 December 31, 2021 Fair Value Fair Value Level 2 - Assets: Real estate investment $ — $ 26,768 Level 3 - Assets: Real estate investments $ — $ 4,970

Per Share Data of HTA (Tables)

Per Share Data of HTA (Tables)	6 Months Ended
	Jun. 30, 2022
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted	The following is the reconciliation of the numerator and denominator used in basic and diluted earnings per share of HTA for the three and six months ended June 30, 2022 and 2021, respectively (in thousands, except per share data): Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Numerator: Net income $ 14,422 $ 38,739 $ 33,088 $ 61,132 Net income attributable to non-controlling interests (254) (728) (605) (1,091) Net income attributable to common stockholders $ 14,168 $ 38,011 $ 32,483 $ 60,041 Denominator: Weighted average shares outstanding - basic 229,074 218,822 229,026 218,787 Dilutive shares - OP Units convertible into common stock 4,051 3,504 4,060 3,510 Adjusted weighted average shares outstanding - diluted 233,125 222,326 233,086 222,297 Earnings per common share - basic Net income attributable to common stockholders $ 0.06 $ 0.17 $ 0.14 $ 0.27 Earnings per common share - diluted Net income attributable to common stockholders $ 0.06 $ 0.17 $ 0.14 $ 0.27

Per Unit Data of HTALP (Tables)

Per Unit Data of HTALP (Tables)	6 Months Ended
	Jun. 30, 2022
Earnings Per Share
Schedule of Earnings Per Unit, Basic and Diluted	The following is the reconciliation of the numerator and denominator used in basic and diluted earnings per share of HTA for the three and six months ended June 30, 2022 and 2021, respectively (in thousands, except per share data): Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Numerator: Net income $ 14,422 $ 38,739 $ 33,088 $ 61,132 Net income attributable to non-controlling interests (254) (728) (605) (1,091) Net income attributable to common stockholders $ 14,168 $ 38,011 $ 32,483 $ 60,041 Denominator: Weighted average shares outstanding - basic 229,074 218,822 229,026 218,787 Dilutive shares - OP Units convertible into common stock 4,051 3,504 4,060 3,510 Adjusted weighted average shares outstanding - diluted 233,125 222,326 233,086 222,297 Earnings per common share - basic Net income attributable to common stockholders $ 0.06 $ 0.17 $ 0.14 $ 0.27 Earnings per common share - diluted Net income attributable to common stockholders $ 0.06 $ 0.17 $ 0.14 $ 0.27
Healthcare Trust of America Holdings, LP (HTALP)
Earnings Per Share
Schedule of Earnings Per Unit, Basic and Diluted	The following is the reconciliation of the numerator and denominator used in basic and diluted earnings per unit of HTALP for the three and six months ended June 30, 2022 and 2021, respectively (in thousands, except per unit data): Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Numerator: Net income $ 14,422 $ 38,739 $ 33,088 $ 61,132 Net income attributable to non-controlling interests — — — — Net income attributable to common unitholders $ 14,422 $ 38,739 $ 33,088 $ 61,132 Denominator: Weighted average OP Units outstanding - basic 233,125 222,326 233,086 222,297 Dilutive units - OP Units convertible into common units — — — — Adjusted weighted average units outstanding - diluted 233,125 222,326 233,086 222,297 Earnings per common unit - basic: Net income attributable to common unitholders $ 0.06 $ 0.17 $ 0.14 $ 0.28 Earnings per common unit - diluted: Net income attributable to common unitholders $ 0.06 $ 0.17 $ 0.14 $ 0.28

Supplemental Cash Flow Inform_2

Supplemental Cash Flow Information (Tables)	6 Months Ended
	Jun. 30, 2022
Supplemental Cash Flow Elements [Abstract]
Schedule of Supplemental Cash Flow Information	The following is the supplemental cash flow information for the six months ended June 30, 2022 and 2021, respectively (in thousands): Six Months Ended June 30, 2022 2021 Supplemental Disclosure of Cash Flow Information: Interest paid, net of capitalized interest $ 50,284 $ 39,827 Cash paid for operating leases 7,609 7,942 Supplemental Disclosure of Noncash Investing and Financing Activities: Accrued capital expenditures $ 6,244 $ 13,065 Dividend distributions declared, but not paid 75,765 71,302 Redemption of non-controlling interest 2,065 546 ROU assets obtained in exchange for lease obligations 705 7,683

Organization and Description _2

Organization and Description of Business (Details)	Jul. 20, 2022 $ / shares shares	Jul. 19, 2022 $ / shares	Jun. 30, 2022 state $ / shares	Dec. 31, 2021 $ / shares
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of states in which the Company operates | state			32
Business Acquisition [Line Items]
Common stock, par value (in dollars per share)			$ 0.01	$ 0.01
Merger Agreement with Healthcare Realty Trust Incorporated | Subsequent Event
Business Acquisition [Line Items]
Common stock, par value (in dollars per share)	$ 0.01
Merger agreement conversion ratio (in shares) | shares	1
Special distribution payment (in dollars per share)		$ 4.82
Healthcare Realty Trust Incorporated | Merger Agreement with Healthcare Realty Trust Incorporated | Subsequent Event
Business Acquisition [Line Items]
Common stock, par value (in dollars per share)	$ 0.01

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Narrative (Details) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022 USD ($) property shares	Jun. 30, 2021 USD ($)	Jun. 30, 2022 USD ($) property shares	Jun. 30, 2021 USD ($)	Dec. 31, 2021 USD ($) property shares	Dec. 31, 2020 USD ($)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]
Cash and cash equivalents	$ 29,714	$ 19,796	$ 29,714	$ 19,796	$ 52,353
Restricted cash	4,559	70,542	4,559	70,542	4,716
Total cash, cash equivalents and restricted cash	34,273	90,338	34,273	90,338	$ 57,069	$ 118,765
Leases [Abstract]
Real estate notes receivable, net	75,900		75,900
Interest income	$ 1,849	121	3,608	264
Expected credit losses			$ 0
Unconsolidated Joint Ventures [Abstract]
Investment in unconsolidated joint ventures, ownership percentage	50%		50%		50%
Investment in unconsolidated joint venture	$ 62,070		$ 62,070		$ 62,834
Income (loss) from unconsolidated joint venture	$ 401	406	801	798
Notes Receivable
Leases [Abstract]
Interest income			$ 3,200
Disposal Group, Held-for-sale
Leases [Abstract]
Number of properties in portfolio | property	0		0		1
Minimum
Leases [Abstract]
Lessor, term of contract	3 years		3 years
Maximum
Leases [Abstract]
Lessor, term of contract	7 years		7 years
Building and Building Improvements
Real estate investments [Abstract]
Depreciation expense	$ 62,300	60,700	$ 124,600	121,900
Healthcare Trust of America Holdings, LP (HTALP)
Partners' Capital Notes [Abstract]
Limited partner's capital, units issued (in shares) | shares	4,050,493		4,050,493		4,142,408
Limited partner's capital, units outstanding (in shares) | shares	4,050,493		4,050,493		4,142,408
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]
Cash and cash equivalents	$ 29,714		$ 29,714		$ 52,353
Restricted cash	4,559		4,559		4,716
Total cash, cash equivalents and restricted cash	34,273	90,338	34,273	90,338	57,069	$ 118,765
Leases [Abstract]
Interest income	1,849	121	3,608	264
Unconsolidated Joint Ventures [Abstract]
Investment in unconsolidated joint venture	62,070		62,070		$ 62,834
Income (loss) from unconsolidated joint venture	$ 401	$ 406	$ 801	$ 798

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Schedule of Notes Receivable (Details)	Jun. 30, 2022 USD ($)
Accounts, Notes, Loans and Financing Receivable [Line Items]
Real estate notes receivable, net	$ 75,900,000
Mezzanine Loans and Mortgage Loan Texas
Accounts, Notes, Loans and Financing Receivable [Line Items]
Outstanding Loan Amount	76,220,000
Accrued interest receivable	311,000
Unamortized fees and costs	(659,000)
Unearned revenue	0
Real estate notes receivable, net	$ 75,872,000
Mezzanine Loans - Texas
Accounts, Notes, Loans and Financing Receivable [Line Items]
Stated Interest Rate	8%
Maximum Loan Commitment	$ 54,119,000
Outstanding Loan Amount	$ 53,756,000
Mezzanine Loan - North Carolina
Accounts, Notes, Loans and Financing Receivable [Line Items]
Stated Interest Rate	8%
Maximum Loan Commitment	$ 6,000,000
Outstanding Loan Amount	$ 6,000,000
Mortgage Loan - Texas
Accounts, Notes, Loans and Financing Receivable [Line Items]
Stated Interest Rate	10%
Maximum Loan Commitment	$ 15,000,000
Outstanding Loan Amount	$ 15,000,000
Construction Loan - Florida
Accounts, Notes, Loans and Financing Receivable [Line Items]
Stated Interest Rate	6%
Maximum Loan Commitment	$ 65,000,000
Outstanding Loan Amount	$ 1,464,000

Investments in Real Estate - Ac

Investments in Real Estate - Acquisitions (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Investments [Abstract]
Aggregate purchase price	$ 25,666	$ 53,025
Closing costs	$ 200

Investments in Real Estate - Pu

Investments in Real Estate - Purchase Price Allocation (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Jun. 30, 2021
Asset Acquisition
Land	$ 3,812	$ 1,093
Building and improvements	19,761	45,629
In place leases	2,121	5,291
Below market leases	(28)	(79)
Above market leases	0	66
ROU assets	0	(1,372)
Net real estate assets acquired	25,666	50,628
Other, net	0	2,397
Aggregate purchase price	$ 25,666	$ 53,025

Investments in Real Estate - We

Investments in Real Estate - Weighted Average Lives (Details)	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Investments [Abstract]
Acquired intangible assets (in years)	4 years 2 months 12 days	4 years 2 months 12 days
Acquired intangible liabilities (in years)	4 years 1 month 6 days	5 years 8 months 12 days

Dispositions and Impairment (De

Dispositions and Impairment (Details) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Jun. 30, 2022 USD ($) property	Jun. 30, 2021 USD ($) derivative property
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gain (loss) on sale of real estate, net	$ 0	$ 32,753	$ (4)	$ 32,753
Impairment	$ 0	$ 16,825	$ 0	$ 16,825
Number of impaired assets | property				2
GEORGIA
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of assets disposed			1	13
Proceeds from the sale of real estate			$ 26,800	$ 67,500
Gain (loss) on sale of real estate, net			$ (4,000)	$ 32,800

Intangible Assets and Liabili_3

Intangible Assets and Liabilities - Summary of Intangible Assets and Liabilities (Details) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Assets:
Gross	$ 403,286	$ 426,251
Accumulated amortization	(210,279)	(213,801)
Total	$ 193,007	$ 212,450
Weighted Average Remaining Amortization in Years	9 years 3 months 18 days	9 years 3 months 18 days
Liabilities:
Accumulated amortization	$ (25,024)	$ (23,742)
Total	$ 28,671	$ 31,331
Weighted Average Remaining Amortization in Years	14 years 7 months 6 days	14 years 3 months 18 days
Below market leases
Liabilities:
Gross	$ 53,695	$ 55,073
Weighted Average Remaining Amortization in Years	14 years 7 months 6 days	14 years 3 months 18 days
In place leases
Assets:
Gross	$ 334,807	$ 349,863
Weighted Average Remaining Amortization in Years	9 years 3 months 18 days	9 years 3 months 18 days
Tenant relationships
Assets:
Gross	$ 47,931	$ 54,851
Weighted Average Remaining Amortization in Years	10 years 10 months 24 days	10 years 9 months 18 days
Above market leases
Assets:
Gross	$ 20,548	$ 21,537
Weighted Average Remaining Amortization in Years	6 years 9 months 18 days	6 years 10 months 24 days

Intangible Assets and Liabili_4

Intangible Assets and Liabilities - Summary of Intangible Amortization (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Amortization recorded against rental income related to above and (below) market leases
Schedule of Finite-Lived Intangible Assets and Liabilities [Line Items]
Amortization of intangible assets and liabilities	$ (634)	$ (641)	$ (1,283)	$ (1,233)
Amortization expense related to in place leases and tenant relationships
Schedule of Finite-Lived Intangible Assets and Liabilities [Line Items]
Amortization of intangible assets and liabilities	$ 9,843	$ 11,340	$ 20,159	$ 23,227

Receivables and Other Assets -

Receivables and Other Assets - Schedule of Receivables and Other Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Receivables and Other Assets [Abstract]
Tenant receivables, net	$ 10,131	$ 10,477
Other receivables, net	10,335	6,098
Deferred financing costs, net	7,697	7,055
Deferred leasing costs, net	48,418	45,008
Straight-line rent receivables, net	149,602	142,604
Prepaid expenses, deposits, equipment and other, net	34,549	38,301
Derivative financial instruments - interest rate swaps	7,721	0
Real estate notes receivable, net	75,872	69,114
Finance ROU asset, net	16,108	16,284
Total	$ 360,433	$ 334,941

Receivables and Other Assets _2

Receivables and Other Assets - Amortization (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Receivables and Other Assets [Abstract]
Amortization expense related to deferred leasing costs	$ 2,296	$ 2,204	$ 4,523	$ 4,427
Interest expense related to deferred financing costs	$ 1,560	$ 431	$ 2,913	$ 862

Leases - Narrative (Details)

Leases - Narrative (Details) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2022 USD ($) lease	Jun. 30, 2021 USD ($)	Jun. 30, 2022 USD ($) lease	Jun. 30, 2021 USD ($)
Leases [Abstract]
Number of new ground leases commenced | lease	1		1
Rental and other revenues from operating lease payments	$ 198	$ 187.4	$ 397.3	$ 377.8
Variable lease payments	$ 47.4	$ 42.2	$ 95.5	$ 87.3

Leases - Maturity of Lease Liab

Leases - Maturity of Lease Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Operating Leases
2022	$ 5,378
2023	10,884
2024	10,411
2025	9,899
2026	9,901
2027	9,886
Thereafter	591,325
Total undiscounted lease payments	647,684
Less: Interest	(450,693)
Present value of lease liabilities	196,991	$ 196,286
Finance Leases
2022	316
2023	635
2024	640
2025	645
2026	656
2027	668
Thereafter	36,856
Total undiscounted lease payments	40,416
Less: Interest	(23,506)
Present value of lease liabilities	$ 16,910

Leases - Lease Revenues and Mat

Leases - Lease Revenues and Maturity of Future Minimum Rents (Details) $ in Thousands	Jun. 30, 2022 USD ($)
Leases [Abstract]
2022	$ 290,284
2023	551,493
2024	495,354
2025	436,400
2026	388,471
2027	318,837
Thereafter	1,345,024
Total	$ 3,825,863

Debt - Schedule of Debt (Detail

Debt - Schedule of Debt (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Debt Instrument
Total debt, gross	$ 3,115,000	$ 3,050,000
Deferred financing costs, net	(16,426)	(17,975)
Discount, net	(3,931)	(3,903)
Total	3,094,643	3,028,122
Unsecured term loans
Debt Instrument
Total debt, gross	500,000	500,000
Unsecured senior notes
Debt Instrument
Total debt, gross	2,550,000	2,550,000
Fixed rate mortgages
Debt Instrument
Total debt, gross	0	0
Unsecured revolving credit facility
Debt Instrument
Unsecured revolving credit facility	$ 65,000	$ 0

Debt - Narrative (Details)

Debt - Narrative (Details) - USD ($)			1 Months Ended			3 Months Ended		6 Months Ended		12 Months Ended
	Feb. 28, 2022	Oct. 06, 2021	May 31, 2022	Sep. 30, 2020	Sep. 30, 2019	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	May 13, 2022	Dec. 31, 2021	Dec. 31, 2017	Jul. 12, 2016
Debt Instrument
Outstanding amount						$ 3,115,000,000		$ 3,115,000,000						$ 3,050,000,000
Loss on extinguishment of debt, net			$ 3,600,000			3,615,000	$ 0	3,615,000	$ 0
Deferred financing costs								7,154,000	0
Healthcare Trust of America Holdings, LP (HTALP)
Debt Instrument
Loss on extinguishment of debt, net						3,615,000	$ 0	3,615,000	0
Deferred financing costs								7,154,000	$ 0
Term Loan Agreement
Debt Instrument
Outstanding amount			1,125,000,000										$ 1,125,000,000
Term Loan Facility
Debt Instrument
Debt financing cost			$ 1,800,000										1,800,000
Unsecured term loans
Debt Instrument
Line of credit facility, borrowing capacity		$ 300,000,000
Outstanding amount						500,000,000		$ 500,000,000						500,000,000
Unsecured term loans | Base Rate
Debt Instrument
Basis spread on variable rate								0.50%
Unsecured term loans | Fed Funds Effective Rate Overnight Index Swap Rate
Debt Instrument
Basis spread on variable rate								1%
Unsecured term loans | SOFR
Debt Instrument
Basis spread on variable rate								0.10%
Unsecured term loans | $300.0 Million Unsecured Term Loan due 2023
Debt Instrument
Basis spread on variable rate								0.95%
Debt issuance costs						1,800,000		$ 1,800,000
Outstanding amount						$ 300,000,000		$ 300,000,000
Weighted average interest rate with interest rate swap impact						2.37%		2.37%
Unsecured term loans | $300.0 Million Unsecured Term Loan due 2023 | Healthcare Trust of America Holdings, LP (HTALP)
Debt Instrument
Outstanding amount						$ 300,000,000		$ 300,000,000
Unsecured term loans | $300.0 Million Unsecured Term Loan due 2023 | LIBOR | Minimum
Debt Instrument
Basis spread on variable rate								0.80%
Unsecured term loans | $300.0 Million Unsecured Term Loan due 2023 | LIBOR | Maximum
Debt Instrument
Basis spread on variable rate								1.60%
Unsecured term loans | $200.0 Million Unsecured Term Loan due 2024 | Healthcare Trust of America Holdings, LP (HTALP)
Debt Instrument
Basis spread on variable rate								1%				65%
Outstanding amount						$ 200,000,000		$ 200,000,000
Weighted average interest rate with interest rate swap impact						2.32%		2.32%
Debt instrument, face amount						$ 200,000,000		$ 200,000,000				$ 200,000,000
Unsecured term loans | $200.0 Million Unsecured Term Loan due 2024 | LIBOR | Minimum | Healthcare Trust of America Holdings, LP (HTALP)
Debt Instrument
Basis spread on variable rate								0.75%
Unsecured term loans | $200.0 Million Unsecured Term Loan due 2024 | LIBOR | Maximum | Healthcare Trust of America Holdings, LP (HTALP)
Debt Instrument
Basis spread on variable rate								1.65%
Unsecured term loans | Term Loan Facility
Debt Instrument
Line of credit facility, borrowing capacity													$ 1,125,000,000
Unsecured senior notes
Debt Instrument
Outstanding amount						2,550,000,000		$ 2,550,000,000						2,550,000,000
Extinguishment of debt								700,000,000
Loss on extinguishment of debt, net											$ 18,300,000
Unsecured senior notes | $600.0 Million Unsecured Senior Notes due 2026 | Healthcare Trust of America Holdings, LP (HTALP)
Debt Instrument
Outstanding amount						600,000,000		600,000,000
Debt instrument, face amount						600,000,000		600,000,000
Debt instrument, stated interest rate					3.50%
Unsecured senior notes | $650.0 Million Unsecured Senior Notes | Healthcare Trust of America Holdings, LP (HTALP)
Debt Instrument
Debt instrument, face amount					$ 650,000,000	650,000,000		650,000,000
Debt instrument, stated interest rate					3.10%
Debt instrument, percentage of principal amount received					99.66%
Debt instrument, effective interest rate					3.14%
Proceeds from issuance of debt								900,000,000
Unsecured senior notes | $250.0 Million Unsecured Senior Notes | Healthcare Trust of America Holdings, LP (HTALP)
Debt Instrument
Proceeds from unsecured senior notes					$ 250,000,000
Debt instrument, percentage of principal amount received					99.72%
Debt instrument, effective interest rate					3.53%
Unsecured senior notes | $350.0 Million Unsecured Senior Notes | Healthcare Trust of America Holdings, LP (HTALP)
Debt Instrument
Debt instrument, face amount																$ 350,000,000
Debt instrument, percentage of principal amount received					103.66%
Debt instrument, effective interest rate					2.89%
Unsecured senior notes | $500.0 Million Unsecured Senior Notes due 2027 | Healthcare Trust of America Holdings, LP (HTALP)
Debt Instrument
Outstanding amount						500,000,000		500,000,000
Debt instrument, face amount						500,000,000		500,000,000							$ 500,000,000
Debt instrument, stated interest rate															3.75%
Debt instrument, percentage of principal amount received															99.49%
Debt instrument, effective interest rate															3.81%
Unsecured senior notes | $800.0 Million Unsecured Senior Notes due 2031 | Healthcare Trust of America Holdings, LP (HTALP)
Debt Instrument
Debt instrument, face amount						800,000,000		800,000,000
Proceeds from unsecured senior notes				$ 800,000,000
Debt instrument, stated interest rate				2%
Debt instrument, percentage of principal amount received				99.20%
Debt instrument, effective interest rate				2.09%
Extinguishment of debt				$ 300,000,000
Loss on extinguishment of debt, net										$ 24,700,000
Deferred financing costs				$ 6,800,000
Unsecured revolving credit facility
Debt Instrument
Unsecured revolving credit facility						65,000,000		65,000,000						$ 0
Unsecured revolving credit facility | Healthcare Trust of America Holdings, LP (HTALP)
Debt Instrument
Conditional maximum borrowing capacity						2,050,000,000		2,050,000,000
Maximum borrowing capacity, conditional increase						750,000,000		$ 750,000,000
Basis spread on variable rate								0.85%
Line of credit facility, commitment fee								0.20%
Debt issuance costs						6,200,000		$ 6,200,000
Unsecured revolving credit facility						$ 65,000,000		$ 65,000,000
Unsecured revolving credit facility | Line of Credit
Debt Instrument
Line of credit facility, borrowing capacity		$ 1,000,000,000
Unsecured revolving credit facility | Line of Credit | Minimum
Debt Instrument
Basis spread on variable rate		0.80%
Line of credit facility, commitment fee		0.125%
Unsecured revolving credit facility | Line of Credit | Maximum
Debt Instrument
Basis spread on variable rate		1.60%
Line of credit facility, commitment fee		0.30%
Unsecured revolving credit facility | Line of Credit | LIBOR | Minimum
Debt Instrument
Basis spread on variable rate		0.725%
Unsecured revolving credit facility | Line of Credit | LIBOR | Maximum
Debt Instrument
Basis spread on variable rate		1.40%
Unsecured revolving credit facility | Line of Credit | Fed Funds Effective Rate Overnight Index Swap Rate | Minimum
Debt Instrument
Basis spread on variable rate		0%
Unsecured revolving credit facility | Line of Credit | Fed Funds Effective Rate Overnight Index Swap Rate | Maximum
Debt Instrument
Basis spread on variable rate		0.60%
Bridge Financing Facility | Line of Credit | Merger Agreement with Healthcare Realty Trust Incorporated
Debt Instrument
Line of credit facility, borrowing capacity	$ 1,700,000,000
Commitment fees	$ 5,400,000

Debt - Principal Maturity Sched

Debt - Principal Maturity Schedule (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Debt Disclosure [Abstract]
2022	$ 0
2023	0
2024	200,000
2025	365,000
2026	600,000
Thereafter	1,950,000
Total	$ 3,115,000	$ 3,050,000

Debt - Amortization of Deferred

Debt - Amortization of Deferred Financing Costs (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Debt Disclosure [Abstract]
2022	$ 1,554
2023	3,107
2024	2,725
2025	2,604
2026	1,839
Thereafter	4,597
Total	$ 16,426	$ 17,975

Derivative Financial Instrume_3

Derivative Financial Instruments and Hedging Activities (Details)	3 Months Ended		6 Months Ended
	Jun. 30, 2022 USD ($) derivative	Jun. 30, 2021 USD ($)	Jun. 30, 2022 USD ($) derivative	Jun. 30, 2021 USD ($)	Dec. 31, 2021 USD ($)
Derivatives, Fair Value
Derivatives expected to be reclassified in the next 12 months	$ 5,600,000		$ 5,600,000
Derivative financial instruments - interest rate swaps	7,721,000		7,721,000		$ 0
Liability Derivatives	0		0		5,069,000
Fair value of derivatives in net asset position, including accrued interest, excluding nonperformance risk adjustment	$ 7,800,000		$ 7,800,000
Designated as Hedging Instrument | Cash Flow Hedging | Interest rate swaps
Derivatives, Fair Value
Number of instruments | derivative	7		7
Notional amount	$ 500,000,000		$ 500,000,000
Gain (loss) recognized in OCI	3,255,000	$ (150,000)	10,473,000	$ 1,013,000
Gain (loss) reclassified from accumulated OCI into income	(830,000)	$ (1,673,000)	(2,429,000)	$ (3,302,000)
Designated as Hedging Instrument | Cash Flow Hedging | Interest rate swaps | Receivables and other assets
Derivatives, Fair Value
Derivative financial instruments - interest rate swaps	7,721,000		7,721,000		0
Designated as Hedging Instrument | Cash Flow Hedging | Interest rate swaps | Derivative financial instruments
Derivatives, Fair Value
Liability Derivatives	$ 0		$ 0		$ 5,069,000

Commitments and Contingencies (

Commitments and Contingencies (Details)	May 02, 2022 defendant
Shiva Stein v. Healthcare Trust of America, Inc., et al.
Loss Contingencies [Line Items]
Number of defendants	2

Stockholders' Equity and Part_3

Stockholders' Equity and Partners' Capital - Narrative (Details)			3 Months Ended				6 Months Ended
	Jul. 06, 2022 $ / shares	Jul. 01, 2022 $ / shares	Jun. 30, 2022 USD ($) $ / shares shares	Mar. 31, 2022 $ / shares	Jun. 30, 2021 USD ($) $ / shares	Mar. 31, 2021 USD ($) $ / shares	Jun. 30, 2022 USD ($) shares	Jun. 30, 2021 USD ($)	Sep. 30, 2020 USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Amount remaining available for issuance under the new ATM			$ 750,000,000				$ 750,000,000
Authorized amount stock repurchase plan									$ 300,000,000
Remaining amount of available for repurchase			300,000,000				300,000,000
Dividend distributions declared, but not paid			$ 75,765,000		$ 71,302,000		75,765,000	$ 71,302,000
Common stock dividends declared (in dollars per share) | $ / shares			$ 0.325	$ 0.325	$ 0.320	$ 0.320
Distributions paid (in dollars per share) | $ / shares	$ 4.82
Operating Partnership distributions paid (in dollars per share) | $ / shares	$ 4.82
Subsequent Event
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock dividends declared (in dollars per share) | $ / shares		$ 0.029
Operating Partnership distributions paid (in dollars per share) | $ / shares		$ 0.029
Common Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Amount remaining available for issuance under the new ATM						$ 750,000,000
Restricted Common Stock
Incentive Plan
Nonvested awards, total compensation cost not yet recognized			$ 6,200,000				$ 6,200,000
Period for recognition (in years)							1 year 7 months 6 days
Restricted Common Stock | Minimum
Incentive Plan
Award vesting period							3 years
Restricted Common Stock | Maximum
Incentive Plan
Award vesting period							4 years
Restricted Common Stock | General and Administrative Expense
Incentive Plan
Compensation expense			$ 2,200,000		$ 2,100,000		$ 4,200,000	$ 5,400,000
Amended and Restated 2006 Incentive Plan
Incentive Plan
Number of shares authorized (in shares) | shares			10,000,000				10,000,000
Number of shares available for grant (in shares) | shares			9,647,839				9,647,839
Healthcare Trust of America Holdings, LP (HTALP)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Dividend distribution ratio							1
Common stock dividends declared (in dollars per share) | $ / shares			$ 0.325	$ 0.325	$ 0.320	$ 0.320

Stockholders' Equity and Part_4

Stockholders' Equity and Partners' Capital - Restricted Common Stock Activity (Details) - Restricted Common Stock - $ / shares	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Restricted Common Stock
Balance as of beginning of period (in shares)	529,862	436,399
Granted (in shares)	158,543	354,288
Vested (in shares)	(124,407)	(270,099)
Forfeited (in shares)	(7,690)	(6,767)
Balance as of end of period (in shares)	556,308	513,821
Weighted Average Grant Date Fair Value
Balance as of beginning of period (in dollars per share)	$ 28.83	$ 28.27
Granted (in dollars per share)	30.81	26.62
Vested (in dollars per share)	27.37	27.48
Forfeited (in dollars per share)	29.58	28.87
Balance as of end of period (in dollars per share)	$ 29.71	$ 27.54

Fair Value of Financial Instr_3

Fair Value of Financial Instruments - Assets and Liabilities Measured on Recurring Basis (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Assets:
Real estate notes receivable, net	$ 75,872	$ 69,114
Derivative financial instruments	7,721	0
Liabilities:
Derivative financial instruments	0	5,069
Debt	3,094,643	3,028,122
Fair Value, Measurements, Recurring | Carrying Amount | Level 2
Assets:
Real estate notes receivable, net	75,872	69,114
Derivative financial instruments	7,721	0
Liabilities:
Derivative financial instruments	0	5,069
Debt	3,094,643	3,028,122
Fair Value, Measurements, Recurring | Fair Value | Level 2
Assets:
Real estate notes receivable, net	72,377	68,476
Derivative financial instruments	7,721	0
Liabilities:
Derivative financial instruments	0	5,069
Debt	$ 2,797,099	$ 3,117,602

Fair Value of Financial Instr_4

Fair Value of Financial Instruments - Assets Measured on Non-Recurring Basis (Details) - Fair Value, Nonrecurring - Fair Value - MOB - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Level 2
Assets:
Real estate investment	$ 0	$ 26,768
Level 3
Assets:
Real estate investment	$ 0	$ 4,970

Per Share Data of HTA (Details)

Per Share Data of HTA (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Numerator:
Net income	$ 14,422	$ 38,739	$ 33,088	$ 61,132
Net income attributable to non-controlling interests	(254)	(728)	(605)	(1,091)
Net income attributable to common stockholders/unitholders	$ 14,168	$ 38,011	$ 32,483	$ 60,041
Denominator:
Weighted average shares/units outstanding - basic (in shares)	229,074	218,822	229,026	218,787
Dilutive shares - partnership units convertible into common stock (in shares)	4,051	3,504	4,060	3,510
Adjusted weighted average number of shares/units outstanding — diluted (in shares)	233,125	222,326	233,086	222,297
Earnings per common share - basic
Net income attributable to common stockholders/unitholders (in dollars per share)	$ 0.06	$ 0.17	$ 0.14	$ 0.27
Earnings per common share - diluted
Net income attributable to common stockholders/unitholders (in dollars per share)	$ 0.06	$ 0.17	$ 0.14	$ 0.27

Per Unit Data of HTALP (Details

Per Unit Data of HTALP (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2022	Jun. 30, 2021
Numerator:
Net income	$ 14,422		$ 38,739		$ 33,088	$ 61,132
Net income attributable to non-controlling interests	(254)		(728)		(605)	(1,091)
Net income attributable to common stockholders/unitholders	$ 14,168		$ 38,011		$ 32,483	$ 60,041
Denominator:
Weighted average shares/units outstanding - basic (in shares)	229,074		218,822		229,026	218,787
Dilutive shares - partnership units convertible into common stock (in shares)	4,051		3,504		4,060	3,510
Adjusted weighted average number of shares/units outstanding — diluted (in shares)	233,125		222,326		233,086	222,297
Earnings per common unit - basic:
Net income attributable to common stockholders/unitholders (in dollars per share)	$ 0.06		$ 0.17		$ 0.14	$ 0.27
Earnings per common unit - diluted:
Net income attributable to common stockholders/unitholders (in dollars per share)	$ 0.06		$ 0.17		$ 0.14	$ 0.27
Healthcare Trust of America Holdings, LP (HTALP)
Numerator:
Net income	$ 14,422		$ 38,739		$ 33,088	$ 61,132
Net income attributable to non-controlling interests	0		0		0	0
Net income attributable to common stockholders/unitholders	$ 14,422	$ 18,666	$ 38,739	$ 22,393	$ 33,088	$ 61,132
Denominator:
Weighted average shares/units outstanding - basic (in shares)	233,125		222,326		233,086	222,297
Dilutive shares - partnership units convertible into common stock (in shares)	0		0		0	0
Adjusted weighted average number of shares/units outstanding — diluted (in shares)	233,125		222,326		233,086	222,297
Earnings per common unit - basic:
Net income attributable to common stockholders/unitholders (in dollars per share)	$ 0.06		$ 0.17		$ 0.14	$ 0.28
Earnings per common unit - diluted:
Net income attributable to common stockholders/unitholders (in dollars per share)	$ 0.06		$ 0.17		$ 0.14	$ 0.28

Supplemental Cash Flow Inform_3

Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Supplemental Disclosure of Cash Flow Information:
Interest paid, net of capitalized interest	$ 50,284	$ 39,827
Cash paid for operating leases	7,609	7,942
Supplemental Disclosure of Noncash Investing and Financing Activities:
Accrued capital expenditures	6,244	13,065
Dividend distributions declared, but not paid	75,765	71,302
Redemption of non-controlling interest	2,065	546
ROU assets obtained in exchange for lease obligations	$ 705	$ 7,683